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     Of the roughly 1 in 8 women that develop breast cancer in their lifetimes, 70% will have 
estrogen receptor a positive (ERa+) cancer. The standard of care for these cancers is endocrine 
therapy, including aromatase inhibitors and selective estrogen receptor modulators and degraders 
(SERMs and SERDs), that either block the production of estrogen or competitively inhibit the 
binding of estrogen to ERa. These small molecule antiestrogens work by inhibiting the pro-
proliferative actions of estrogen but after years of treatment, many cancers recur as resistant 
tumors. Recently, we discovered a non-competitive modulator of ERa that works in a strikingly 
different way. BHPI acts through ERa to hyperactivate a lethal anticipatory unfolded protein 
response (UPR), hijacking a normally protective and pro-proliferative action of estrogen and ERa. 
We have found that BHPI effectively inhibits proliferation of and kills breast cancer cells 
expressing constitutive and antiestrogen resistant mutations, ERaY537S and ERaD538G, that are 
common in metastatic breast cancer and upregulate the UPR. Surprisingly, BHPI does not kill 
cancer cells through classical UPR activated, CHOP-mediated, caspase-dependent apoptosis, but 
rather through necrosis initiated by ATP depletion. This death pathway includes rapid swelling of 
ERa+ cancer cells and release of arachidonic acid, and is downstream of calcium release from the 
endoplasmic reticulum (EnR). Interestingly, preliminary data suggests that necrotic products 
released from cells treated with BHPI may act as markers of inflammation that activate immune 
cells. Strong and sustained activation of the anticipatory UPR leading to necrotic cell death and 
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CHAPTER 1: INTRODUCTION 
This work contains previously published material.1 
 
Abstract  
Cells react to a variety of stresses, including accumulation of unfolded or misfolded protein, by 
activating the endoplasmic reticulum (EnR) stress sensor, the unfolded protein response (UPR). 
The UPR is highly conserved and plays a key role in the maintenance of protein folding quality 
control and homeostasis. In contrast to the classical reactive mode of UPR activation, recent 
studies describe a hormone-activated anticipatory UPR. In this pathway, mitogenic hormones such 
as estrogen (E2), epidermal growth factor (EGF), and vascular endothelial growth factor (VEGF) 
rapidly activate the UPR in anticipation of a future need for increased protein folding capacity 
upon cell proliferation. Here, I focus on this recently unveiled pathway of E2-estrogen receptor a 
(ERa) action. Notably, rapid activation of the anticipatory UPR pathway is essential for 
subsequent activation of the E2-ERa regulated transcription program. Moreover, activation of the 
UPR at diagnosis is a powerful prognostic marker in ERa positive breast cancer. Lethal ERa-
dependent hyperactivation of the anticipatory UPR represents a promising therapeutic approach 
exploited by a novel small molecule ERa biomodulator, BHPI, and may be effective against 
recently identified ERaY537S and ERaD538G mutations common in metastatic breast cancer. 




                                               




     The endoplasmic reticulum (EnR) plays a key role in the synthesis, folding, and transport of 
proteins and is important in lipid synthesis.1,2 Maintenance of protein folding and lipid homeostasis 
is critical for cell proliferation and viability. The unfolded protein response (UPR) is an EnR stress-
response pathway that senses and responds to diverse stimuli, including changes in EnR luminal 
calcium, redox status, nutrient availability, lipid bilayer composition, and accumulation of 
unfolded or misfolded protein.3,4 The UPR consists of three arms, IRE1a, ATF6a, and PERK, that 
together decrease the flux of new protein into the EnR while simultaneously increasing production 
of molecular chaperones to help fold unfolded or misfolded proteins. IRE1a and PERK are 
activated upon oligomerization and autophosphorylation. ATF6a is activated and transported to 
the Golgi apparatus, where it is cleaved by S1P and S2P proteases, although the mechanism of 
activation in the EnR is still unclear. There is increasing evidence that all three arms of the UPR 
can be activated in more than one way. For example, some of the earliest work suggested that the 
molecular chaperone, BiP, blocked oligomerization and activation of IRE1a and PERK through 
direct binding to their luminal domains.2 Upon accumulation of unfolded or misfolded proteins, 
BiP would be competed away, allowing activation of these UPR arms. Similarly, it is thought that 
upon depletion of EnR calcium, calcium-dependent molecular chaperones, such as BiP, fall off 
IRE1a and PERK, and other unfolded or misfolded proteins. This would allow IRE1a and PERK 
to oligomerize and activate the UPR.5 Additional experiments and elucidation of the crystal 
structure of the luminal domain of IRE1a showed that independent of BiP binding, IRE1a can 
directly bind and be activated by peptides via an MHC-like structural domain.2 Interestingly, recent 
work has also suggested that IRE1a and PERK may sense and be activated by changes in lipid 
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content of the EnR membrane, independent of accumulation of unfolded protein or depletion of 
calcium in the EnR.6 
     Activation of the non-canonical RNase IRE1a (inositol-requiring enzyme 1a) results in 
alternative splicing of the transcription factor XBP1, leading to the production of spliced-XBP1 
(sp-XBP1) and upregulation of molecular chaperones.7 ATF6a (activating transcription factor 6a) 
is translocated to the Golgi apparatus where it is cleaved by proteases to produce the transcription 
factor p50-ATF6a that also upregulates chaperone production.8 Lastly, activated PERK (protein 
kinase RNA-like endoplasmic reticulum kinase) phosphorylates eIF2a, resulting in transient 
inhibition of most protein synthesis while promoting translation and production of selective 
proteins including ATF4, CHOP, p58IPK, and GADD34.9 When UPR stress is mild, the chaperone 
p58IPK binds to and inhibits PERK, and GADD34 dephosphorylates eIF2a. Working together, 
p58IPK and GADD34 reverse PERK activation and restore protein synthesis. 
     Classically, the UPR is activated in response to EnR stress. Several years ago, it was shown 
that progenitors of immunoglobulin-producing B cells activate the UPR before initiating antibody 
production.10,11 This pathway, which is activated in absence of unfolded protein, was named the 
anticipatory UPR by Peter Walter and David Ron,2 but it was not studied extensively. We, and 
others, recently showed that diverse steroid and peptide hormones including estrogen (17b-
estradiol, E2), progesterone (P4), epidermal growth factor (EGF), and vascular endothelial growth 
factor (VEGF), and probably the insect hormone ecdysone (Ec), activate an anticipatory UPR 
pathway to prepare cells for the increased protein folding that accompanies cell proliferation.12–16 
Notably, the steps between hormone-receptor complexes and activation of the three arms of the 
UPR have largely been identified.12–14 
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    The proliferative and anti-apoptotic advantage of overexpressing or activating hormone 
receptors, such as EGF receptor (EGFR) or estrogen receptor a (ERa), has long been appreciated 
in cancer biology.17–20 However, hormone activation of the anticipatory UPR has only recently 
become a focus of cancer research and exploited as a therapeutic target. Here, we focus on the role 
of E2-ERa activation of the anticipatory UPR and a promising preclinical drug candidate, BHPI, 
which leverages this novel action of ERa in order to block proliferation of and kill most ERa 
positive breast cancer cells. 
 
Activation of the anticipatory UPR by mitogenic hormones 
     Steroid and peptide hormones exert their effects through binding and modulating their specific 
receptors.20,21 Using E2-ERa as an example, when hormone receptors bind their ligand, they 
dimerize and are recruited to specific DNA response elements (Figure 1). E2-ERa then modulates 
the activity of thousands of genes either through direct binding to DNA, or by tethering of E2-ERa 
to other transcription factors.22–24 The genomic actions of E2-ERa are important for the pro-
proliferation properties of E2 in ERa positive breast cancer cells and while rapidly initiated, play 




Figure 1. Intracellular actions of mitogenic hormones. Estrogen (E2) and epidermal growth factor 
(EGF) act on their respective receptors, ERa and EGFR, to initiate crosstalk between extranuclear 
signaling pathways and their genomic programs. ERa indirectly and EGFR directly activate 
phospholipase C g (PLCg), resulting in cleavage of PIP2 to DAG (diacylglycerol) and IP3 (inositol 
triphosphate). IP3 then binds to IP3 receptors (IP3Rs) in the endoplasmic reticulum (EnR) 
membrane, causing moderate efflux of calcium from the lumen of the EnR into the cell body. This 
calcium signal activates all three arms of the unfolded protein response (UPR) and acts as an 
authorizing signal for E2-ERa and EGF-EGFR modulation of gene expression and cell 
proliferation. In parallel, E2-ERa and EGF-EGFR modulate additional extranuclear signal 
transduction pathways, including activation of ERK and Akt signaling. Activation of these 
pathways is also important for subsequent cell proliferation and crosstalks with the E2-ERa and 
EGF-EGFR genomic programs. 
 
     In addition to classical genomic actions, E2-ERa exerts rapid extranuclear actions important 
for activating signal transduction pathways (Figure 1). These pathways are important for diverse 
actions of E2-ERa, crosstalk with the genomic program, and are rapidly activated and often play 
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out over minutes to hours.25,26 Of these pathways, activation of the anticipatory UPR is the most 
recently described (Figure 1).14 Upon binding of E2 to ERa at the plasma membrane, there is rapid 
activation of phospholipase C g (PLCg), resulting in cleavage of its substrate PIP2 to IP3 (inositol 
triphosphate) and DAG (diacylglycerol). The IP3 then binds to and opens IP3 receptor (IP3R) 
calcium channels in the membrane of the EnR, allowing efflux of calcium out of the lumen of the 
EnR into the cell body. The modest decrease in EnR calcium caused by E2 treatment of ERa 
positive cancer cells weakly activates the UPR, resulting in upregulation of molecular chaperones 
along with minimal and very transient inhibition of protein synthesis. By knockdown of UPR 
components, or blocking calcium release from the EnR, we showed that increased intracellular 
calcium from activation of the anticipatory UPR is critical for subsequent E2-ERa-mediated 
modulation of gene expression and cell proliferation.14 
     In diverse cancers, mild UPR activation is protective and helps cancers proliferate, induce 
angiogenesis, and overcome hypoxia and toxic stress from chemotherapies.27,28 Using microarray 
and outcome data from approximately 1,000 patient breast cancers, we demonstrated the 
significance of this pathway in ERa positive breast cancer. Increased expression of a UPR gene 
index consisting of UPR-components and UPR-induced chaperones strongly correlated with 
reduced time to recurrence, subsequent resistance to tamoxifen, and reduced survival.14 The close 
correlation between the extent of activation of the UPR gene index and activation of E2-ERa 
regulated genes is consistent with ERa playing a major role in the elevated expression of the UPR 
gene index.29 Moreover, in triple negative breast cancer in which ERa is absent, the IRE1/XBP1 
axis plays a central role in tumorigenicity and progression, and the extent of activation of an XBP1 
gene index is correlated with reduced patient survival.30,31 Taken together, this suggests that ERa-
mediated activation of the anticipatory UPR likely plays an important role in early survival of 
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breast cancers. At later times when therapeutic stress is added to nutritional deprivation and 
hypoxia, activation of the classical reactive UPR makes an important contribution to tumor 
survival.28,32–34 
   Because of the protective nature of the UPR in cancer, drugs that target components of the UPR 
are in pre-clinical development, in clinical trials, and have been approved.30,31,35 Most commonly, 
these drugs inhibit key components of the UPR such as PERK, IRE1a RNase, or the downstream 
chaperone BiP/GRP78. Unfortunately, due to lack of drug specificity, these drugs may have toxic 
effects in tissues with a large secretory burden, such as pancreas.  
 
UPR hyperactivation as a tool to selectively target ERa positive breast cancer 
     Recently, we described a novel small molecule biomodulator, BHPI, that selectively targets 
ERa positive cancer cells.15,29,36 BHPI (3,3-bis(4-hydroxyphenyl)-7-methyl-1,3,dihydro-2H-
indol-2-one) is a bis-phenylated oxoindol. In a limited structure-activity-relationship (SAR) study, 
addition of methyl groups to both phenyl rings significantly disrupted activity of BHPI.29 We 
demonstrated specificity by testing over 30 ERa positive and negative cell lines and showed that 
BHPI only inhibits proliferation of or kills cells that express ERa.29 Additionally, in the isogenic 
human breast cell lines MCF10A (ERa negative) and MCF10AER IN9 (ERa positive), we showed 
that BHPI was only effective in the cells expressing ERa, and was ineffective when ERa was 
knocked back down in MCF10AER IN9 cells. Demonstrating that BHPI physically interacts with 
ERa, BHPI shifts the tryptophan emission spectrum of ERa and protects peptides in the ERa 
ligand binding domain from protease digestion. Furthermore, BHPI inhibits recruitment of ERa 
to E2-ERa regulated promoters (Figure 2). However, BHPI is not a competitive inhibitor, as it 
does not compete with radiolabeled E2 for the ligand binding pocket and is equally effective in the 
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presence and absence of estrogen.29 Rather than inhibiting a component of the UPR, BHPI takes 
advantage of the already moderately-elevated UPR in cancer cells by hyperactivating the 
anticipatory UPR (Figure 2). BHPI therefore hijacks the normal protective actions of ERa 
activation of the UPR in order to push UPR activation into the lethal range. This is the first small 
molecule to modulate the action of a hormone receptor in this way. 
 
 
Figure 2. Activation of the anticipatory unfolded protein response by ERa. E2-ERa and 
constitutively active ERa mutants activate a mild and protective anticipatory unfolded protein 
response (UPR) and the non-competitive biomodulator BHPI binds ERa and induces 
hyperactivation of this pathway leading to cell death. ERa indirectly activates phospholipase C g 
(PLCg), resulting in cleavage of PIP2 to DAG (diacylglycerol) and IP3 (inositol triphosphate). E2-
ERa and constitutively active ERa mutants cause moderate IP3 production whereas BHPI causes 
significantly more production of IP3. The IP3 then binds to IP3 receptors (IP3Rs) in the endoplasmic 
reticulum (EnR) membrane, causing efflux of calcium from the lumen of the EnR into the cell 
body. E2-ERa and constitutively active ERa mutants cause moderate and transient release of 
calcium, resulting in weak and transient activation of all three arms of the unfolded protein 
response (UPR). Weak UPR activation results in very mild and transient inhibition of protein 
synthesis, production of molecular chaperones, and is critical for subsequent cell proliferation. 
BHPI-ERa induced hyperactivation of the UPR causes robust and sustained release                  
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Figure 2 (cont.) of calcium from the EnR. This leads to robust PERK activation and rapid, 
sustained, and near-quantitative inhibition of protein synthesis. Although BHPI causes 
upregulation of chaperone mRNA, no protein is made, and the UPR-activating signal is never 
resolved. In an effort to re-establish cellular calcium homeostasis, ATP-dependent SERCA pumps 
in the EnR actively transport calcium back into the lumen of the EnR but since IP3Rs remain open, 
an ATP-depleting futile cycle ensues. Decreased cellular ATP and increased AMP activate AMPK, 
which along with calcium, activates Ca2+/calmodulin-dependent kinase, eukaryotic elongation 
factor 2 kinase (CAMKIII/eEF2K). eEF2K then phosphorylates eEF2 (eukaryotic elongation 
factor 2), causing inhibition of protein synthesis at elongation. Ultimately, BHPI-ERa induced 
hyperactivation of the anticipatory UPR causes death of ERa positive endometrial and breast 
cancer cells. 
 
     We showed that BHPI blocks proliferation of ovarian cancer cells and kills most ERa positive 
breast and endometrial cancer cells.15,29,36 Compared to E2, BHPI causes increased production of 
IP3 in cancer cell lines.29,36 This increased production of IP3 hyperactivates the UPR through 
sustained opening of IP3R calcium channels in the EnR, resulting in robust and sustained calcium 
release from the lumen of the EnR into the cell body (Figure 2). While E2 causes mild and transient 
inhibition of protein synthesis, BHPI causes a rapid, sustained, and near-quantitative inhibition of 
protein synthesis in ERa positive breast and endometrial cancer cells. Surprisingly, BHPI also 
causes rapid depletion of intracellular ATP. Disruption of cytosolic calcium homeostasis can be 
toxic, specifically, high levels of calcium can lead to cell death.37–39 To restore intracellular 
calcium homeostasis after opening of IP3Rs, ATP-dependent SERCA pumps in the EnR membrane 
pump calcium back into the EnR lumen, but because IP3Rs remain open, the calcium leaks back 
out. This creates a futile cycle of calcium leakage and pumping that depletes intracellular ATP. 
Additionally, ATP depletion from prolonged SERCA pump activity results in increased levels of 
cellular AMP that activates the metabolic sensor AMPK. AMPK activation together with high 
levels of cytosolic calcium activate the Ca2+/calmodulin-dependent kinase, eukaryotic elongation 
factor 2 kinase (CAMKIII/eEF2K). Activated eEF2K then phosphorylates eukaryotic elongation 
factor 2 (eEF2), which inhibits protein synthesis at a second site (Figure 2). Therefore, although 
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BHPI increases the mRNA levels of chaperones such as BiP and p58IPK, no protein is made, 
leading to un-resolvable cytotoxic activation of the UPR. While other activators of the classical 
reactive UPR share similarities to BHPI’s mechanism of action, such as disruption of EnR calcium 
homeostasis and inhibition of protein synthesis,1,2 BHPI is unique in its ability to cause ATP 
depletion in cancer cells. 
     In ovarian cancer, a common mechanism for resistance to the taxane paclitaxel and other 
chemotherapy agents is overexpression of ATP-dependent efflux pumps, especially Multidrug 
Resistance Protein 1 (MDR1)/P-glycoprotein/ABCB1. Despite intensive efforts, effective and 
non-toxic MDR1 inhibitors have remained elusive. Due to its ability to deplete intracellular ATP, 
BHPI inhibited ATP-dependent MDR1-mediated drug efflux and restored sensitivity of multidrug 
resistant breast and ovarian cancer cells to killing by therapeutically relevant concentrations of 
several anticancer drugs.36 Using multidrug resistant OVCAR-3 cells, BHPI was tested in an 
orthotopic ovarian cancer xenograft model. Although paclitaxel was ineffective against these 
tumors, BHPI alone strongly reduced tumor growth. Notably, tumors were undetectable in mice 
treated with BHPI plus paclitaxel. After the combination therapy, plasma levels of the widely used 
cancer biomarker, CA125, were at least several hundred-fold lower than in mice with control 
tumors. Moreover, CA125 levels progressively declined to undetectable in all mice treated with 
the combination therapy.36 
     The standard of care for ERa positive breast cancer is endocrine therapy, including aromatase 
inhibitors that block E2 production, and tamoxifen and fulvestrant/ICI that compete with E2 for 
binding to ERa. Unfortunately, many tumors that were initially responsive recur after years of 
treatment. Moreover, there is selection and outgrowth of endocrine therapy resistant tumors 
expressing ERa mutations in about one-third of patients with advanced metastatic breast cancer, 
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most commonly ERaY537S and ERaD538G.40–42 Structural and biophysical studies suggest that 
estrogen receptors containing these mutations are stabilized in the active conformation and have 
lower affinity for antiestrogens such as OHT.43 Additionally, a growing body of clinical evidence 
suggests that mutations in this ligand binding domain hotspot confer partial resistance to endocrine 
therapies.40–42,44 Strikingly, patients whose tumors express ERaY537S or ERaD538G have on 
average 12 and 6 months shorter survival, respectively, than patients whose tumors express wild-
type ERa.45 Because of the resistance to endocrine therapies observed in cancers expressing 
ERaY537S and ERaD538G, development of better selective estrogen receptor modulators and 
degraders (SERMs and SERDs) has been a focus in targeting these cancers.46–49 It was not known 
whether BHPI could effectively target these cells. 
      
Hyperactivation of the anticipatory UPR and cell death 
     While the initial steps of BHPI-hyperactivation of the anticipatory UPR are well described, the 
consequences for cell fate were unclear, especially in cancer cells expressing the ERaY537S or 
ERaD538G mutations. Most small molecules that target the classical reactive UPR kill cells by 
activating caspase-dependent apoptosis.50–52 This pathway is characterized by UPR activation 
inducing production of the pro-apoptotic effector, CHOP, that downregulates Bcl2 to initiate 
apoptosis.53 Disruption of calcium homeostasis and mitochondrial dysregulation are also 
associated with UPR-induced apoptosis. Apoptosis is characterized by formation of the 
apoptosome, autoactivation and cleavage of caspase-9, the subsequent cascade of caspase 
activation including caspase-3, and breakdown of cellular components.54 Morphologically, 
apoptosis is characterized by cell shrinking, DNA condensation, and formation of apoptotic bodies. 
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     Many of the small molecules that activate the classical UPR also induce autophagy. Autophagy 
is often a protective mechanism used to cope with cellular stress but when left unchecked, can 
result in cell death, especially in cells that are deficient in the apoptotic machinery. Autophagic 
cell death is characterized by increased production of LC3-II and other markers such as Beclin-1, 
as well as visualization of LC3-II puncta in the initial stages of autophagosome formation. Changes 
in cell morphology include formation of many double-membraned autophagosomes filled with 
cellular debris.33,55 
     Lastly, although less well-understood and less common, cells can die through necrosis. Unlike 
programmed cell death, where cells go through a series of defined steps, necrosis is generally 
thought of as accidental death. Necrosis is characterized by calcium dysregulation, cell swelling, 
loss of membrane integrity, and eventual release of cytosolic contents into the surrounding 
area.38,56 Recent studies have suggested that necroptosis, a subset of necrotic cell death, may 
represent the first example of programmed necrosis. 
     The fate of cells that have experienced strong and sustained activation of the anticipatory UPR 
following BHPI treatment was unknown. Uncovering the death pathway activated by BHPI is not 
only important to understanding its action as a pre-clinical anti-cancer drug. Although this type of 
death has not been described in normal physiology, understanding this pathway might shed light 
on how accidentally-prolonged activation of the anticipatory UPR under normal conditions, such 
as in immunoglobulin-producing B cells,10,11 might lead to cell death. 
 
Conclusion 
     Studies of the pro-proliferative effects of mitogenic hormones and their respective receptors 
have long focused on their actions on genomic programs and on extranuclear signal transduction 
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pathways. Activation of the anticipatory UPR is an emerging, very rapid action of many mitogenic 
hormones that authorizes subsequent gene expression and cell proliferation. Important for 
targeting hormone receptor positive breast cancers is the finding that they exhibit elevated UPR 
activation. This UPR activation can be exploited by small molecules that hyperactivate the 
pathway, pushing UPR activation into the lethal range. As a first-in-class small molecule, BHPI is 
a model for investigating hyperactivation of the anticipatory UPR as a promising strategy for 
killing ERa positive breast cancer cells. A similar approach is also likely viable for breast cancers 
that overexpress other hormone receptors that activate the anticipatory UPR, such as progesterone 
receptor, or EGFR family members. However, agents that hyperactivate the anticipatory UPR 
through these receptors have yet to be identified. Thus, the anticipatory UPR is a key pathway for 




CHAPTER 2: MATERIALS AND METHODS 
 
Cell culture and reagents. Cell culture medium and conditions were as previously described.57 
T47D, MCF7, ECC-1, MDA MB-231, HeLa, ES2, HEK 293T, and MCF10A cells were from 
ATCC. BT-474 cells were provided by Dr. R. Schiff, MCF10AER IN9 cells were provided by Dr. 
B.H. Park, and TamR cells were provided by Dr. D. McDonnell. T47D-ERaY537S (TYS) and 
T47D-ERaD538G (TDG) were made as we recently described.15 Cells were grown in the 
following conditions: T47D (MEM, 10% FBS), ERaY537S and ERaD538G (MEM, 10% 
charcoal:dextran-treated (CD)-FBS), MCF-7 (MEM, 5% FBS), ECC-1 (RPMI, 5% FBS), MDA 
MB-231 (MEM, 5% FBS), HeLa (RPMI1640, 10% FBS), ES2 (McCoy’s 5a, 10% FBS), HEK 
293T (DMEM, 10% FBS), MCF10A (2% CD-FBS, 20ng/ml EGF), BT-474 (RPMI1640, 10% 
FBS), and TamR (DMEM/F12 +NEAA +100 nM z-OHT, 8% FBS). Reagents used were: ICI 
182,780 (Tocris Biosciences, UK), trans-ISRIB, SKF 96365, and BAPTA-AM (Cayman 
Chemical, MI), fulvestrant/ICI 182,780 (Tocris Bioscience, MN), bortezomib, 7-Cl-O-Nec-1, and 
GSK872 (EMD Millipore, MA), niflumic acid, quinacrine dihydrochloride, and Z-VAD-FMK 
(Santa Cruz Biotechnology, TX), 3H-arachidonic acid and 35S-methionine (Perkin Elmer, MA), all 
other reagents were from Sigma Aldrich (MO). 
 
Generation of ERαY537S and ERαD538G cell lines. Our protocol was loosely based on 
previous work.58 Two guide sequences (Supplementary Fig. S1) were cloned into pSpCas9(BB)-
2A-Puro(PX459) (Addgene, MA). An HDR template with mutations was cloned into pUC18, and 
linearized before transfection. Two plasmids with guide sequences and the HDR template carrying 
either the ERaY537S or ERaD538G mutation were co-transfected into T47D cells. After 3-day 
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selection in 2.5 µg/ml puromycin, followed by 3 weeks of E2-free growth, colonies were 
transferred to a 24-well plate. Clones were genotyped at the DNA and mRNA levels using PCR 
and restriction enzyme digestion. Sequencing confirmed selected clones. Oligonucleotide 
sequences and additional details are in Supplementary Methods. 
 
MTS cell proliferation assay. Cell proliferation assays in 2D culture were performed as 
described.29 Briefly, 2,000 cells/well were incubated with treatment for 4 days with one medium 
change after 2 days. After 4 days, 20 µl of CellTiter 96 Aqueous One Solution (Promega, WI) was 
added to each well and absorbance measured. 
 
Quantitative proliferation assays in 3D culture. Quantitative assays of colonies in soft agar were 
as in59 with minor modifications. Briefly, 2,000 cells in 60 µl 0.4% agar were plated in 96-well 
plates above 50 µl 0.6% agar. Cells were grown for 5 days with one medium change, treated with 
AlamarBlue (Fisher, NH) and fluorescence measured. 
 
Alamar Blue Cell Proliferation Assay 
Cells were plated at the indicated density into 96-well plates. The next day, the medium was 
changed to one containing the indicated treatment. The medium was changed again after 2 days 
and proliferation assayed after a total of 4 days. Cell number was measured with Alamar Blue 







Western blotting was carried out as previously described.14,57 The following primary antibodies 
were used: PARP (Cell Signaling Technology (CST) #9532), Bcl2 (CST #4223), LC3A/B (CST 
#4108), Beclin-1 (CST #3738), CHOP (CST #2895), p-p70S6K (T389) (CST # 9234), ERα (CST 
# 8644), HMGB1 (Novus Biologicals, 2F6), PLCγ (CST #5690), and β-actin (Sigma, A1978). 
Antibodies were probed with HRP-conjugated secondary antibodies (ThermoFisher) and imaged 
with the ECL2 detection kit (Fisher Scientific, MA) using a PhosphorImager. 
 
Trypan Blue Exclusion and Cell Swelling 
Cell viability or cell diameter after treatment with BHPI or other compounds were measured using 
a Countess II cell counter (ThermoFisher). 300 000 cells/well were plated in 6-well plates. The 
next day, vehicle or treatment was added for the indicated time. Cells were then harvested and 
concentrated to 2-5 million cells/ml before addition of trypan blue immediately before counting 
for cell viability or diameter. 
 
Lentiviral Production 
Constructs for packaging vectors pCI-VSVG (#1733) and psPAX2 (#12260), pHIV-Luciferase 
(#21375), and pCDH-Bcl2 (#46971) were from Addgene (MA). Lentiviral packaging vectors were 
co-transfected with either luciferase or Bcl2 into HEK 293T cells with Lipofectamine 3000 
(Invitrogen, CA). The next day, medium was changed. Virus was harvested 24 hours later and 






300 000 cells/well were plated in 6-well plates. The next day, vehicle or treatment was added for 
the indicated time. Cells were then harvested, washed with PBS, and stained with the Dead Cell 
Apoptosis Kit (ThermoFisher). After staining, cells were measured on a BD LSR II (BD 
Biosceinces, NJ) and data was analyzed using FCS Express (DeNovo, CA). 
 
Transmission Electron Microscopy 
The cell pellet was fixed in a Karnovsky's Fixative in phosphate-buffered 2% glutaraldeyde and 
2.5 % paraformaldehyde. Microwave fixation was used with this primary fixative and the tissue 
was then washed in Sorenson’s phosphate buffer without additives. Microwave fixation was also 
used with the secondary 2% osmium tetroxide fixative, followed by the addition of 3% potassium 
ferricyanide for 30 minutes. After washing with water, saturated uranyl acetate was added for 
enbloc staining. The tissue was dehydrated with a series containing increasing concentrations of 
ethanol. Acetonitrile was used as the transition fluid between ethanol and the epoxy. Infiltration 
series was done with an epoxy mixture using the epon substitute Lx112. The resulting blocks were 
polymerized at 90 °C overnight, trimmed and ultrathin sectioned with diamond knives. Sections 
were stained with uranyl acetate and lead citrate and examined or photographed with a Hitachi 
H600 Transmission Electron Microscope at 75KV. 
 
Lactate Dehydrogenase (LDH) Release 
LDH release into the medium was measured according to the CytoTox-ONE Homogeneous 




siRNA Knockdown of ERα and PLCγ 
Knockdown of ERα or PLCγ was performed using DharmaFECT1 transfection reagent and 100 
nM ON-TARGETplus non-targeting pool or SMARTpool for ERα (ESR1) or PLCγ (PLCG1) 
(Dharmacon, CO). T47D or TYS cells were treated with non-coding or coding siRNA for 16 hours 
and the medium was replaced thereafter. To further reduce the levels of ERα, 24 hours after 
changing the medium, 1 µM of ICI was added to the samples that received ERα siRNA and vehicle 
was added to the untreated and non-coding samples. Cell swelling was assayed after an additional 
24 hours. Trypan blue uptake in TYS cells was measured 48 hours following transfection. 
 
Protein Synthesis 
Rates of protein synthesis were evaluated by measuring 35S-methionine incorporation into newly 
synthesized protein as described previously.29 Briefly, cells were incubated with treatment for the 
indicated time and 3 µCi 35S-methionine was added for the last 30 min of treatment. Cells were 
washed with PBS and lysed in RIPA buffer. Lysates were spun and supernatants were pipetted 
onto Whatman 540 filter-paper discs and subsequently washed 3X each with 10% TCA, then 5% 
TCA, and air dried. Protein was solubilized and counts were measured to determine percent protein 
synthesis inhibition. 
 
3H-Arachidonic Acid Release from Cell Membranes 
Phospholipase cleavage of arachidonic acid (AA) from membranes was determined by measuring 
release of 3H-AA into medium. To allow overnight incorporation into membranes, 100 000 
cells/well were plated in a 24-well plate and incubated overnight in medium containing 0.1% fatty 
acid-free BSA and 3H-AA to a final concentration of 0.1 µCi/ml. The next day, the medium was 
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removed, and cells were washed 4X with incubation medium (25 mM HEPES pH 7.2, 150 mM 
NaCl, 5 mM KCl, 5.5 mM dextrose, 0.8 mM MgSO4, 1 mM CaCl2, 0.1% BSA). Incubation 
medium containing the treatment was added and cells were incubated at 37 °C for 45 minutes. 
Medium was collected, and cells were lysed in 0.1 M NaOH. 3H counts for the medium and cell 
lysate were determined and AA release was normalized to total incorporated label. 
 
BHPI-Stimulated Prostaglandin Release 
Cells were plated to 70% confluency; the next day, the medium was changed to MEM + 0.1% 
BSA with treatment. 24 hours later, the medium was collected, spun down, and the supernatant 
was collected and evaporated before resuspension and analysis following the Prostaglandin 
Screening Kit protocol (Cayman Chemical). 
 
ATP Measurement 
ATP depletion was performed as previously described29 and ATP levels were measured according 
to the ATPlite Luminescence Assay Kit protocol (Perkin Elmer). 
 
mRNA Induction and Migration of THP-1 Cells 
T47D or TYS cells were grown to 70-80% confluency. Cells were washed once with PBS, and the 
medium was replaced with serum-free medium containing the indicated treatment. After 24 hours, 
the conditioned medium was taken, spun down to remove cell debris, and the supernatant was 
collected for further use. BHPI was added to the control conditioned medium after isolation. 
Raptinal-treated T47D or TYS cells were treated for 4 hours before washing the small molecule 
out to eliminate apoptotic effects on THP-1 cells. For mRNA experiments, THP-1 cells were 
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differentiated in 10 nM phorbol-12-myristate-13-acetate (PMA) for 3 days. The following day, 
medium was replaced. 24 hours later, conditioned medium was added to a final volume of 1:1 with 
normal culture medium and RNA was extracted after 6 hours.  
     To measure migration, THP-1 cells were spun down and resuspended in serum-free medium. 
200,000 cells were plated in the upper well of a Boyden chamber in 100 µL volume. 400 µL of 
conditioned medium was added to the bottom of each well, and the cells were allowed to migrate 
for 4 hours. After 4 hours, migration was measured with the QCM Chemotaxis 5 µm 24-Well Cell 






CHAPTER 3: ANTIESTROGEN RESISTANT CELL LINES EXPRESSING ESTROGEN 
RECEPTOR α MUTATIONS UPREGULATE THE UNFOLDED PROTEIN RESPONSE 
AND ARE KILLED BY BHPI 
This work contains previously published material.2 
 
Abstract 
Outgrowth of metastases expressing ERa mutations Y537S and D538G is common after endocrine 
therapy for estrogen receptor a (ERa) positive breast cancer. The effect of replacing wild type 
ERa in breast cancer cells with these mutations was unclear. We used the CRISPR-Cas9 genome 
editing system and homology directed repair to isolate and characterize 14 T47D cell lines in which 
ERaY537S or ERaD538G replace one or both wild-type ERa genes. In 2-dimensional, and in 
quantitative anchorage-independent 3-dimensional cell culture, ERaY537S and ERaD538G cells 
exhibited estrogen-independent growth. A progestin further increased their already substantial 
proliferation in micromolar 4-hydroxytamoxifen and fulvestrant/ICI 182,780 (ICI). Our recently 
described ERa biomodulator, BHPI, which hyperactivates the unfolded protein response (UPR), 
completely blocked proliferation. UPR-regulated proteins associated with tamoxifen resistance, 
including the oncogenic chaperone BiP/GRP78, were upregulated. ICI displayed a greater than 2-
fold reduction in its ability to induce ERaY537S and ERaD538G degradation. Progestins, UPR 
activation and perhaps reduced ICI-stimulated ERa degradation likely contribute to antiestrogen 
resistance seen in ERaY537S and ERaD538G cells.
                                               





Endocrine therapy for estrogen receptor a (ERa) positive breast cancers employs aromatase 
inhibitors to block estrogen production and tamoxifen and fulvestrant/Faslodex/ICI 182,780 (ICI) 
that compete with estrogens for binding to ERa. For advanced metastatic breast cancer, selection 
and outgrowth of tumors resistant to endocrine therapy and expressing ERa mutations ERaY537S 
and ERaD538G is common.40,41,44,60 There is compelling evidence these mutations are resistant to 
aromatase inhibitors.40–42,44,60–62 While most evidence suggests they are also clinically resistant to 
tamoxifen and fulvestrant/ICI,60,63,64 recent studies demonstrated increased prevalence of ERa 
mutations in breast cancers of patients treated with aromatase inhibitors, but not in patients treated 
with fulvestrant,42 or tamoxifen.61 These researchers question the association of ERa mutations 
with clinical resistance to fulvestrant and tamoxifen. In studies mostly using transfected ERa 
negative cells, the mutants were reported to be resistant to tamoxifen and ICI,60 resistant to 
tamoxifen but sensitive to ICI41 and sensitive to antiestrogen inhibition.40,65 Previously described 
systems for analyzing the ERaY537S and ERaD538G mutations were not ideal. Cell lines derived 
from circulating tumor cells exhibit multiple genetic changes and lack a control cell line. 
Transfected ERa negative cell lines do not exhibit estrogen-ERa regulated proliferation and 
display a different ERa-regulated gene expression pattern than ERa positive breast cancer cells.66 
A better experimental model would compare cells expressing the ERa mutations and wild type 
ERa in a defined genetic background in an ERa positive breast cancer cell whose proliferation is 
stimulated by estrogen. We therefore used the CRISPR-Cas9 gene editing system to produce 
multiple cell lines in which one or both copies of the wild type ERa gene was replaced by 
ERaY537S or ERaD538G.  
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     Although the most common application of the CRISPR-Cas9 system is targeted gene 
inactivation by non homologous end joining (NHEJ) to repair the Cas9 generated DNA break, 
when a homologous repair donor is present, a homology-directed repair process (HDR) can 
precisely insert a sequence containing the desired modification into the gene of interest. Because 
the frequency of HDR is usually extremely low,67–71 the CRISPR-Cas9 system has rarely been 
used to successfully repair or insert specific mutations in both copies of endogenous genes in a 
cancer cell line. We used the CRISPR-Cas9 gene editing system to generate 50 clonal cell lines 
with one or both copies of endogenous wild-type ERa replaced with ERaY537S or ERaD538G. 
     Although progesterone reportedly plays a role in breast cancer progression,72,73 a recent study 
concluded that when E2 is present, progesterone enhances tamoxifen’s effectiveness as an 
antiestrogen.74 The effect of progestins in cells expressing ERa mutations had not been explored. 
   We showed that the estrogen, 17b-estradiol (E2), acts through ERa to elicit extremely rapid 
and functionally important anticipatory activation of the endoplasmic reticulum stress sensor, the 
unfolded protein response (UPR).14 Moreover, activation of a UPR gene index at diagnosis is a 
powerful prognostic indicator, tightly correlated with subsequent resistance to tamoxifen 
therapy.14 This ERa-regulated UPR pathway is targeted by BHPI, our recently described 
noncompetitive ERa biomodulator. BHPI hyperactivates the UPR, converting it from 
cytoprotective to cytotoxic.29,36 While BHPI is effective in tamoxifen-resistant breast cancer cells 
expressing wild type ERa, its effectiveness in cells expressing ERa mutations associated with 
metastases was unknown.  
     Here we describe the effects of OHT, ICI and BHPI on proliferation of the ERaY537S and 
ERaD538G cells in anchorage dependent and anchorage independent culture with and without a 
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progestin, and evaluate estrogen-independent and progestin-stimulated UPR activation and 
reduced ERa degradation as potential contributors to antiestrogen resistance. 
 
Results  
Using CRISPR-Cas9 to replace wild-type ERa with ERaY537S or ERaD538G.  
     Our strategy is illustrated in Figure 3. To facilitate identification of cells in which the mutant 
ERa fragment replaced the wild-type ERa fragment, we inserted AclI and SpeI sites into the HDR 
template.  
    We chose T47D cells because they contain 2 copies of the ERa gene and exhibit E2 dependent 
growth.75 Previous transfection studies suggested ERaY537S and ERaD538G cells grow without 
E2.40,41,44 We exploited this phenotype during outgrowth and selection of colonies of ERaY537S 
and ERaD538G cells. 
    Individual colonies were pulled, grown out, and genotyped. Genomic DNA spanning the HDR 
template was amplified and analyzed by digestion with AclI or SpeI (Figure 3). 50 of 65 clonal 
cell lines contained single or double gene replacements (Figure 4). Expression of the ERa 
mutations in mRNA was confirmed by synthesizing and digesting cDNA, followed by sequencing 
(Figure 3). We used ERaY537S-4 and ERaD538G-1 as representative clones, as their properties 
matched other ERaY537S and ERaD538G clones. Sequencing and Western blotting with N-
terminal ERa antibody showed that NHEJ introduced diverse indels in the non-replaced copy of 
ERa (Figures 3 and 4). We therefore focused primarily on double replacement cell lines.  
     Western blotting to compare ERa levels in parental T47D cells to levels of ERaY537S and 
ERaD538G in single and double replacement cell lines showed some heterogeneity in expression 
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level of ERaY537S and ERaD538G. The ERa mutations were expressed at levels similar to or 
lower than wild-type ERa (Figure 4). 
 
Figure 3. CRISPR-Cas9 replacement of wild-type ERa with ERaY537S and ERaD538G. (a) 
Design of the HDR template for gene replacement. The ERa genomic fragment containing part of 
intron 7 and exon 8 was amplified by PCR, sequenced and compared to database sequences. Blue 
nucleotides indicate the native or mutated PAM sequence. The single nucleotide changes do not 
alter the amino acid sequence of ERa or use rare codons. These changes will block cutting of the 
edited gene by Cas9. Guide sequences are in red. Underlined regions indicate single nt changes to 
generate AclI or SpeI sites that do not alter the amino acid sequence. The changes to yield the 
desired mutations were: ERaY537S: TAT to TCT (orange); ERaD538G: GAC to GGG (green). 
(b) Genotyping of cell lines: Analysis of genomic DNA and cDNA from clonal cell lines for 
restriction sites indicating gene replacement. Genomic DNA or cDNA generated from total RNA 
was used as template for PCR amplification with ERa specific primers. The PCR primers were 
outside the HDR template or corresponding mRNA region. PCR products from each clone     
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Figure 3 (cont.) were subjected to AclI or SpeI digestion. Digestion patterns after agarose gel 
electrophoresis and staining with ethidium bromide are shown for 14 randomly chosen clones, 8 
from Y537S and 6 from D538G. (c) Identification of insertions and deletions (indels) in the non-
replaced copy of ERa. The undigested (SpeI and AclI) DNA bands from cell lines in which one 
copy of wild-type ERa was replaced (single replacement) were purified by agarose gel 
electrophoresis and sequenced. For both guide sequences, the Cas9 cleavage site is noted. Inserted 
nucleotides are underlined and deletions are shown by dots. The sequence of all digested bands 
are as designed (not shown). In ERaY537S-4 one ERa gene is missing the SpeI site and 
sequencing confirmed the presence of the ERaY537S mutation and mutation of both PAM 
sequences. Therefore, we can confirm two distinct and independent events replaced both copies of 
wild-type ERa. This also suggests a homologous recombination event between the restriction site 
and the PAM sequence. Since sequencing the undigested SpeI ERaY537S-4 band confirmed the 
ERaY537S and PAM sequence mutations, one of the two homologous recombination events 
occurred in the 50 nucleotide region between the Y537S mutation and SpeI site. This is the only 
recombination event observed within 50 bp of the mutation site among all 50 clones (1 out of 130 
possible recombination events [potentially 4 recombination events/double replacement]). Thus, 





Figure 4. Summary of CRISPR-Cas9 gene replacement. (a) Table 1 summarizes data for all the 
clonal cell lines genotyped. Despite the low frequency of HDR for both the ERaY537S and 
ERaD538G mutations, almost half as many assayed cell lines had both copies of the wild-type 
ERa replaced with the mutation as cell lines that had one copy replaced. Although we did not 
observe a substantial growth advantage for the double replacement cell lines in standard cell 
culture, it remains possible that they exhibited a somewhat larger growth advantage during 
outgrowth of the clones. The reason for the small number of false positive cell lines in the       
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Figure 4 (cont.) ERaD538G experiments is unknown. (b) Western blot analysis of ERa 
expression. To ensure detection of deletions and truncations in the C-terminal region of ERa, we 
used an antibody recognizing epitopes in the N-terminal region of ERa. The Western blot shows 
that the pattern of ERa gene expression in the cell lines replacing one copy of the ERa gene 
matches that predicted from the DNA sequencing. For example: In Supplementary Figure S1c, 
clones ERaD538G-4 and ERaD538G-5 show a deletion of 17 amino acids and a reading frame 
shift after the deletion. This results in a protein, containing 588 amino acids with almost 60 amino 
acids after a reading frame shift. This protein’s size is very close to the size of wild-type ERα as 
seen by two bands in the western (595 aa). For clones D538G-6, Y537S-5 and Y537S-8, a single 
nt insertion causes a reading frame shift and premature termination, resulting in truncation of the 
protein. For these 3 clones, this insertion results in a protein with 537 total amino acids seen as a 
second, lower molecular weight band than wild-type ERα. For clones Y537S-6 and Y537S-7, there 
are deletions and reading frame shifts, resulting in a protein containing 579 amino acids. On the 
gel, the ERα band is broad and blurry, suggesting two bands. 
 
ERaY537S and ERaD538G cells exhibit E2-independent growth and partial resistance to 
OHT and ICI.  
     Although the clonal cell lines were isolated and maintained without E2, it was unknown whether 
E2 further stimulates their growth. As expected, the parental T47D cells exhibited little growth 
without E2 and dose-dependent increases in growth with E2 (Figure 5a).29 The ERaY537S-4 cells 
and the other ERaY537S cell lines were completely E2-independent for growth. E2 further 
stimulated the more modest E2-independent proliferation of ERaD538G-1 and other ERaD538G 
cells (Figures 5a and 6).  
     We next performed dose response studies evaluating the effect of OHT and ICI on proliferation 
of the T47D, ERaY537S and ERaD538G cell lines. To facilitate comparisons, T47D and mutant 
cells were maintained in medium containing E2. In T47D cells, OHT and ICI nearly abolished 
proliferation at a 50-1,000 fold molar excess over E2 (Figure 5b,c). In contrast, the mutant cell 
lines, especially ERaY537S-4, exhibited some resistance (Figure 5b,c; blue bars). Additionally, 
while T47D cells displayed negligible growth in ICI, all seven ERaY537S and ERaD538G double 
replacement cell lines displayed at least some growth in ICI (Figure 6). In longer 8-day cultures, 
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Figure 5. In standard anchorage-dependent 2D culture, ERaY537S-4 and ERaD538G-1 cells 
exhibit E2-independent proliferation and partial resistance to OHT and ICI. (a) Dose-response 
study comparing the effects of increasing concentrations of E2 on the proliferation of T47D, 
ERaY537S-4 and ERaD538G-1 cells. (b and c) Dose-response studies comparing the effects of 
increasing concentrations of OHT (b) and ICI (c) on the proliferation of T47D, ERaY537S-4 and 




Figure 6. In standard 2D culture, additional ERαY537S and ERαD538G cells exhibit partial 
resistance to OHT and ICI. Dose-response studies comparing the effects of increasing 
concentrations of OHT (a) and ICI (b) on the proliferation of T47D and additional double 






Figure 7. In longer-term 2D culture, ERαY537S-4 and ERαD538G-1 cells exhibit continued 
proliferation in the presence of ICI and OHT, but not with BHPI. 1,000 cells were seeded into each 
well of a 96-well plate. The next day (day 0), treatment was started. Medium with treatment was 
changed every two days. Data is mean ± SEM (n=8). Slopes of the lines were compared using the 
free online calculator (http://www.danielsoper.com/statcalc/calculator.aspx?id=103). ***: 
p<0.001. Statistics were calculated using all collected data (not mean values) comparing the slope 
of the T47D line to either ERαY537S-4 or ERαD538G-1. Slopes were calculated by linear 
regression and are as follows- OHT: T47D: 300 ± 22, ERαY537S-4: 593 ± 25, ERαD538G-1: 437 
± 28; ICI: T47D: 214 ± 17, ERαY537S-4: 441 ± 17, ERαD538G-1: 375 ± 18; BHPI: T47D: 37 ± 
14, ERαY537S-4: -172 ± 7, ERαD538G-1: 9 ± 15. 
 
BHPI blocks growth of ERaY537S and ERaD538G cells.  
     Since the ERaY537S and ERaD538G cell lines displayed partial resistance to OHT and ICI, 
we evaluated the ability of our recently described noncompetitive ERa biomodulator, BHPI, to 
inhibit proliferation of ERaY537S and ERaD538G cells.29 At 25 nM, BHPI completely inhibited 
proliferation of T47D, ERaY537S-4 and ERaD538G-1 cells and the 14 characterized ERa mutant 
cell lines (Figures 8a and 9). In longer 8-day cultures, BHPI continued to completely block 





Figure 8. ERaY537S-4 and ERaD538G-1 cells show antiestrogen resistant growth in 2D and 3D 
culture, but are killed by BHPI. (a) Dose-response study of the effect of BHPI on the proliferation 
of T47D, ERaY537S-4 and ERaD538G-1 cells in standard anchorage-dependent 2D culture. (b) 
In 2D culture, R5020 reduces the ability of OHT and ICI to inhibit proliferation of ERaY537S-4 
and ERaD538G-1 cells. (c) In 3D culture, ERaY537S-4 and ERaD538G-1 cells are highly 
antiestrogen resistant and resistance is robustly increased by R5020, but the cells are killed by 
BHPI. Conditions (a-c) as noted, with 100 pM E2 unless otherwise stated. Data is mean ± SEM 
(n=8). For (b,c) *:p<0.05, **: p< 0.01, ***: p< 0.001 (by Student’s T test) comparing treatment to 
treatment + R5020. 
 
 
Figure 9. BHPI blocks proliferation and often kills ERαY537S and ERαD538G cells with or 
without added E2. (a) Dose-response studies showing 25 nM BHPI is effective in inhibiting 
proliferation of ERαY537S and ERαD538G cells in the absence of E2. (b) Dose-response studies 
showing all double and single gene replacement ERαY537S and ERαD538G cell lines are 
responsive to BHPI in the presence of E2. Independent of the presence of ERα deletions in the non-
replaced copy of the single replacement cell lines, or of the formation of ERα heterodimers, BHPI 
retains full effectiveness and blocks proliferation of every ERα mutant cell line characterized. Data 




ERaY537S and ERaD538G cells exhibit progesterone-stimulated antiestrogen-resistant, 
BHPI-sensitive, growth in anchorage-independent culture.  
     Although anchorage-independent growth in 3-dimensional (3D) culture is a hallmark of cancer, 
it has been difficult to study quantitatively. Modifying earlier methods,59 we developed a protocol 
for quantitative assessment of cell proliferation in a more biologically relevant anchorage-
independent 3D culture in soft agar.  
    We compared the effects of OHT (1 µM; 10,000 fold excess over E2), ICI (1 and 5 µM), BHPI 
(100 nM) and the synthetic progestin R5020 (10 nM), on proliferation of ERaY537S-4 and 
ERaD538G-1 cells in anchorage-dependent 2D and anchorage-independent 3D culture. 5 µM 
OHT was not used because it exhibits nonspecific toxicity.76–78 In standard 2D culture, the 
ERaY537S-4 cells exhibited reduced, but significant proliferation in OHT and ICI, which was 
increased by R5020. The ERaD538G-1 cells exhibited little proliferation in OHT and ICI, which 
increased slightly in R5020 (Figure 8b, compare open bars: no R5020, hatched bars: + R5020).  
    In quantitative 3D culture, ICI was more effective than OHT in blocking growth of T47D cells. 
Impressively, proliferation of the mutants in 1 µM OHT and ICI was >50% of control, a dramatic 
increase compared to 2D culture (Figure 8c). At 1 µM, ICI was no more effective than OHT in 
inhibiting proliferation of the mutants. Notably, in 3D culture, ERaY537S-4 and ERaD538G-1 
cells grown in R5020 were completely resistant to growth inhibition by 1 µM OHT and ICI (Figure 
8c).  
     In both 2D and 3D culture, BHPI stopped growth and killed the ERaY537S-4 and ERaD538G-
1 cells grown with or without R5020 (Figure 8a-c). Neither growth in a progestin, nor growth in 
3D culture, impaired BHPI’s impressive ability to block growth and kill ERaY537S-4 and 
ERaD538G-1 cells.  
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ICI 182,780 exhibits a reduced ability to induce degradation of ERaY537S and ERaD538G.  
     ICI induces ERa degradation. Since the ERaY537S-4 and ERaD538G-1 cells were ICI 
resistant in 3D culture, we examined the effect of ICI and other ligands on levels of ERaY537S 
and ERaD538G. In the presence of E2, wild-type ERa exhibited modest down-regulation, which 
was less evident in the mutants. OHT is a weak agonist and stabilizes ERa. OHT increased levels 
of ERaY537S but had little effect on the level of ERaD538G. There was a highly significant >2 
fold reduction in the ability of ICI to induce degradation of both the double and single replacement 
ERaY537S and ERaD538G mutants (Figures 10a,b and 11). 
 
 
Figure 10. ERaY537S and ERaD538G exhibit altered ligand-dependent degradation. (a) Western 
blot comparing the effects of E2, OHT and ICI on levels of ERa in T47D, ERaY537S-4 and 
ERaD538G-1 cells. Cells were treated with vehicle (C) or 10 nM E2 (18 hr), or with 1 µM OHT 
or 1 µM ICI (24 hr). (b) Quantitation of densitometry of ERa levels in ligand-treated T47D, 
ERaY537S and ERaD538G double replacement cell lines, within each cell line treatments were 
compared to vehicle control. Data is mean ± SEM (ERaY537S: n=4 cell lines; ERaD538G: n=3 
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Figure 10 (cont.) cell lines; T47D n=3 experiments); b: p< 0.01 (by Student’s T test), for each 




Figure 11. Effects of ligand on ERα degradation in all single and double replacement ERαY537S 
and ERαD538G cell lines. (a) Western blot analysis (25 µg/lane) and (b) Densitometry of ERα 
levels in ligand-treated T47D, ERaY537S and ERaD538G cell lines, within each cell line 
treatments were compared to vehicle. Data in (b) is mean ± SEM (ERaY537S: n=8 cell lines; 
ERaD538G: n=6 cell lines; T47D: n=3 experiments); b: p< 0.01, c: p< 0.001 (by Student’s T test), 
for each treatment, comparing mutant to wild-type ERα in T47D cells. 
 
Markers of UPR activation are elevated in ERaY537S and ERaD538G cells.  
     E2 elicits a weak anticipatory activation of the UPR that is a strong prognostic marker correlated 
with tamoxifen resistance.14,79,80 The effect of P4 on the UPR had not been explored. We therefore 
investigated the effect of estrogen and progesterone on UPR markers in the tamoxifen-resistant 
ERaY537S-4 and ERaD538G-1 cells. Activation of the UPR’s ATF6a and IRE1a arms induces 
the strongly oncogenic chaperone BiP/GRP78/HSPA5 by 1.5-3 fold (Figure 12a,c).81,82 Activation 
of these UPR arms also induces the anti-apoptotic protein p58IPK.83–85 Pooling data from all 14 
mutant cell lines, BiP was significantly elevated in ERaY537S cells and p58IPK was elevated in 
both ERaY537S and ERaD538G cells (Figure 12b,c). Interestingly, progesterone receptor (PR) 
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was constitutively elevated to levels higher in ERaY537S and ERaD538G cells than in E2-treated 
T47D cells (Figure 12d). P4 significantly induced levels of BiP and p58IPK in T47D cells and 
further increased p58IPK in ERaY537S-4 cells, but neither BiP nor p58IPK were significantly 
further induced in ERaD538G-1 cells (Figure 12e). Thus, progesterone further increases 
expression of some, but not all, UPR markers. 
 
Figure 12. The UPR is activated in ERaY537S-4 and ERaD538G-1 cells and is further activated 
by progesterone. (a,b) Western blots (left) and quantitation (right) showing BiP and p58IPK 
induction in all ERaY537S and ERaD538G cell lines. (c) Western blot showing induction of BiP 
and p58IPK in ERaY537S-4 and ERaD538G-1 cells. (d) Progesterone receptor is highly 
upregulated in ERaY537S-4 and ERaD538G-1 cells. (e) BiP is strongly induced and p58IPK is 
induced by P4 in T47D cells, p58IPK but not BiP is induced by P4 in ERaY537S-4 cells and neither 
is significantly induced by P4 in ERaD538G-1 cells. For (a-e) T47D cells were treated with vehicle 
or 10 nM E2 for 24 hr, mutant cell lines were treated with vehicle. In (e) T47D cells were treated 
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Figure 12 (cont.) with vehicle for 48 hr or with E2 for 24 hr to induce PR then P4 for 24 hr; 
ERaY537S-4 and ERaD538G-1 cells were treated with vehicle or P4 for 24 hr. Data is mean ± 
SEM. In (a,b) ERaY537S: n=8 cell lines; ERaD538G: n=6 cell lines; T47D n=3 experiments. In 
(c,e) quantitation shown below is from the average of three identical blots. *: p< 0.05, **: p< 0.01, 
***: p< 0.001 (by Student’s T test), for each treatment, comparing each mutant to wild-type 
vehicle control (a-d) or comparing vehicle treated to P4 within each cell line (e). 
 
Discussion  
While the CRISPR-Cas9 genome editing system has been widely used to inactivate genes,86–91 
gene replacement studies often use a few cell lines exhibiting unusually high HDR frequency.69–
71,92 While our use of 2 guide sequences to increase the frequency of HDR may increase the 
possibility of off-target events,93–95 our ability to confirm key observations in 4 ERaY537S and 3 
ERaD538G clonal cell lines strongly suggests that the observed properties are due to ERa gene 
replacement. Because indirect evidence suggests long templates might increase HDR,96 we used 
double-stranded templates with 1.2 kb arms, not the short ~50 bp single stranded arms usually 
used in HDR.58  
   Consistent with the frequency of error-prone NHEJ being much higher than the frequency of 
HDR,67–71 all sequenced single replacement clones contained indels in the non-HDR ERa copy. 
Since ERa in these clones may exist in heterodimers, in which the indel-containing ERa monomer 
is non-functional, we focused on the double replacement cell lines. Notably, ~30% of cell lines 
replaced both copies of ERa. This suggests each wild-type ERa copy may undergo multiple NHEJ 
events before an indel destroys the guide-matched DNA region or a rare HDR event inactivates 
the PAM sequence.  
    This work exploited our ability to select for multiple clones expressing ERa mutants that grew 
out in the absence of E2. Based on calculations from our large sample size, it seems feasible, but 
very challenging, to replace genes in typical breast cancer cell lines without a selection. Recent 
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studies, largely in HEK293 cells, describe methods for increasing the probability of HDR using 
inhibitors of NHEJ or silencing key molecules involved in NHEJ and optimized HDR templates 
that target the asymmetric mechanism of Cas9.69–71 
     Our data indicates that the ERaY537S and ERaD538G mutations are sufficient to convert an 
ERa positive cancer cell, exhibiting E2-dependent proliferation and growth inhibition by 
antiestrogens, to one exhibiting E2-independent proliferation and resistance to high concentrations 
of OHT and ICI. Importantly, since these experiments were the initial exposure of the ERaY537S 
and ERaD538G cells to antiestrogens, there was no prior selection for other changes favoring 
antiestrogen resistance. Consistent with earlier work, E2-independent proliferation will make 
tumors expressing these mutations resistant to aromatase inhibitors.  
     In more biologically relevant anchorage-independent 3D culture, the ERaY537S and 
ERaD538G cell lines exhibited robust proliferation in the presence of 1 µM z-OHT and 1 µM 
fulvestrant/faslodex/ICI 182,780 (Figure 8d). Notably, the mutant cell lines continued to 
proliferate in 5 µM ICI. Since serum ICI in patients is 20-30 nM,97,98 it is unlikely tumors can 
concentrate ICI to levels that exceed the 1 and 5 µM in which the mutant cell lines proliferate in 
3D culture.  
    It is widely accepted that ICI is a more nearly pure antagonist than OHT. Since OHT stabilizes 
and ICI induces degradation of ERa, the ~9 fold lower level of ERa in ICI-treated compared to 
OHT-treated cells likely makes an important contribution to the increased effectiveness of ICI in 
T47D cells. However, in the ERaY537S and ERaD538G cell lines, ICI was no more effective in 
blocking cell growth than OHT, and ICI exhibited a greater than 2 fold reduced ability to induce 
degradation of the mutant ERas. Instead of the ~9 fold higher level of ERa in OHT-treated versus 
ICI-treated T47D cells, the difference in mutant ERa levels was reduced to 2-3 fold. The 
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diminished ability of ICI to induce degradation of the ERa mutants likely contributes to ICI 
resistance of ERaY537S and ERaD538G cells. Notably, the ERaY537N mutation is also resistant 
to ICI-induced degradation.99 However, in a very recent report, ERaD538G in one patient’s 
circulating tumor cells was not resistant to degradation.100 This suggests that ICI-induced ERa 
degradation may also depend on subtle genetic differences in tumors. Of note, using double 
replacement cell lines may facilitate degradation studies; using current antibodies it is not possible 
to distinguish between wild type ERa and the mutant ERas containing these single amino acid 
changes. 
     OHT is an antagonist because it induces a different conformational change in ERa than E2. 
Very recently, using structural, computational and biophysical approaches Greene and coworkers 
suggested that the ERaY537S and ERaD538G mutations confer partial antiestrogen resistance 
because they exhibit reduced affinity for OHT and because they induce a constitutively active 
conformation that resists deformation by OHT. Moreover, they suggested that ICI, which disorders 
helix 12 of ERa, might be a therapeutically effective antagonist, blocking activity of ERaY537S 
and ERaD538G.43 They also report that ERaY537S is in a conformation that exhibits higher 
constitutive binding of coactivators than ERaD538G.43 Our experimental data on differences in 
proliferation between the ERaY537S and ERaD538G cell lines is consistent with their proposed 
differences in coactivator interaction. Supporting the view that ERaY537S and ERaD538G are in 
a constitutively active conformation that resists antiestrogens, proliferation in 3D culture is 
constitutive and largely resistant to saturating OHT and ICI. 
     In breast cancer cells expressing wild type ERa and PR, progesterone increases stemness and 
markers associated with therapy resistance.72 Moreover, progesterone can be mitogenic and 
mediate cell survival in 3D cultures.72 However, recent xenograft and explant studies show that 
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when estrogen is present, progestins enhance sensitivity of breast cancers expressing wild type 
ERa to tamoxifen.74 Consistent with an earlier study,101 PR was constitutively expressed to 
extremely high levels in the ERaY537S and ERaD538G cells, suggesting it might play an 
important role. We report that a progestin decreases sensitivity of ERaY537S and ERaD538G 
cells to growth inhibition by OHT and ICI in both 2D and 3D culture. In 3D cultures treated with 
a progestin, 1 µM OHT and ICI have lost the ability to inhibit proliferation of ERaY537S and 
ERaD538G cells. Since progestin had little ability to reverse OHT and ICI inhibition of T47D cell 
growth, the progestin effect is likely related to the ERaY537S and ERaD538G mutations. 
Consistent with the possibility that serum progestin might influence antiestrogen resistance in 
women whose breast cancers express the ERaY537S and ERaD538G mutations, progesterone 
levels in post-menopausal women are 0.6-3 nM.102–104 Moreover, breast cancer cells expressing 
both ERa and PR, or overexpressing PR alone, may be sensitive to very low concentrations of 
hormone.72,73 Since the ERaY537S and ERaD538G cells constitutively express very high levels 
of PR, the low serum concentrations of progestins in postmenopausal women together with high 
PR could well have functional effects on antiestrogen resistance in metastatic breast cancers 
expressing ERa mutations.  
    Weak activation of the UPR is protective in cancer and is associated with a poor prognosis, 
while extensive and sustained UPR activation by BHPI is toxic.29,36,79,80 Since we cannot currently 
analyze protein levels in cells from 3D cultures in soft agar, the UPR studies were carried out in 
standard 2D cell culture. The ERaY537S cells exhibited constitutive activation of the IRE1a arm 
of the UPR, as indicated by estrogen-independent induction of the oncogenic chaperone BiP. In 
contrast, the ERaD538G cells exhibited a much smaller induction of BiP. This is consistent with 
the ERaD538G mutant showing a lower level of constitutive growth and antiestrogen resistance 
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in cell proliferation. Since our 2D cell culture data shows that ERaY537S cells exhibit significant 
resistance to OHT and ICI and the ERaD538G cells exhibited very little resistance (Figure 8c), 
this data is consistent with a link between constitutive UPR activation and antiestrogen resistance. 
However, while constitutive UPR activation likely contributes to the antiestrogen resistant 
phenotype seen in the ERaY537S and ERaD538G cell lines, the extent to which it does is unclear, 
and effects are likely complex. 
     In 2D culture R5020 increased proliferation of the ERaY537S and ERaD538G cells in OHT 
and ICI; in 3D culture, R5020 abolished growth inhibition by OHT and ICI. This effect of 
progestin-PR may not only be mediated through further activation of the UPR but also through 
modulation of ERa action and PR’s own transcriptomic program.74 Although further study is 
needed, progestins seem likely to enhance antiestrogen effectiveness in cancer cells expressing the 
ERaY537S and ERaD538G mutations. 
     Although the mutations exhibit an altered ERa conformation,5 and are close to the proposed 
BHPI binding site,29 BHPI was as effective in blocking proliferation of all 14 of the ERaY537S 
and ERaD538G cell lines as it was in T47D cells. Moreover, in 3D culture where the ERaY537S-
4 and ERaD538G-1 cells exhibited robust proliferation in 1 µM OHT and ICI, 100 nM BHPI 
completely blocked proliferation and killed the cells.  
     We used the CRISPR-Cas9 genome editing system to generate precise replacements of both 
copies of a steroid receptor gene. Breast cancer cell lines expressing these ERa mutations 
associated with metastatic breast cancer are highly resistant to endocrine therapy. Taken together, 
our data and the recent structural and biophysical studies suggest that a constitutively active ERa 
conformation, altered ICI-induced degradation of ERa, progestin and UPR activation may all 
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contribute to the antiestrogen resistant phenotype. Notably, the preclinical drug candidate BHPI 




CHAPTER 4: STRONG AND SUSTAINED ACTIVATION OF THE ANTICIPATORY 
UNFOLDED PROTEIN RESPONSE INDUCES NECROTIC CELL DEATH 
This work contains previously published material.3 
 
Abstract 
The endoplasmic reticulum stress sensor, the unfolded protein response (UPR), regulates 
intracellular protein homeostasis. While transient activation of the reactive UPR by unfolded 
protein is protective, prolonged and sustained activation of the reactive UPR triggers CHOP-
mediated apoptosis. In the recently characterized, evolutionarily conserved anticipatory UPR, 
mitogenic hormones and other effectors pre-activate the UPR; how strong and sustained activation 
of the anticipatory UPR induces cell death was unknown. To characterize this cell death pathway, 
we used BHPI, a small molecule that activates the anticipatory UPR through estrogen receptor α 
(ERα) and induces death of ERα+ cancer cells. We show that sustained activation of the 
anticipatory UPR by BHPI kills cells by inducing depletion of intracellular ATP, resulting in 
classical necrosis phenotypes, including plasma membrane disruption and leakage of intracellular 
contents. Unlike reactive UPR activation, BHPI-induced hyperactivation of the anticipatory UPR 
does not induce apoptosis or sustained autophagy. BHPI does not induce CHOP protein or PARP 
cleavage, and two pan-caspase inhibitors or Bcl2 overexpression have no effect on BHPI-induced 
cell death. Moreover, BHPI does not increase expression of autophagy markers, or work through 
recently identified programmed-necrosis pathways, such as necroptosis. Opening of endoplasmic 
reticulum IP3R calcium channels stimulates cell swelling, cPLA2 activation, and arachidonic acid 
                                               
3 Livezey, M. et al. Cell Death & Differentiation, 2018. Data in Figures 13(c-e), 14(a,e), 16(a,b), 17(a,b), 18(a,c,d), 




release. Notably, cPLA2 activation requires ATP depletion. Importantly, blocking rapid cell 
swelling or production of arachidonic acid does not prevent necrotic cell death. Rapid cell death is 
upstream of PERK activation and protein synthesis inhibition, and results from strong and 
sustained activation of early steps in the anticipatory UPR. Supporting a central role for ATP 
depletion, reversing ATP depletion blocks rapid cell death, and the onset of necrotic cell death is 
correlated with ATP depletion. Necrotic cell death initiated by strong and sustained activation of  
the anticipatory UPR is a newly discovered role of the UPR. 
 
Introduction 
    The unfolded protein response (UPR) is an endoplasmic reticulum (EnR) stress-response 
pathway that maintains protein folding homeostasis and quality control. Three UPR arms, PERK, 
IRE1α, and ATF6α, act together to decrease the flux of new protein into the EnR, while 
upregulating molecular chaperones that help fold protein.2,27 Due to its protective effects when 
weakly activated, the UPR is implicated in the development of numerous cancers.3,28,80,81 In this 
reactive mode of UPR activation, accumulation of unfolded or misfolded protein triggers UPR 
activation. A different pathway of UPR activation, originally identified in immune cells and 
recently shown to be activated by the mitogenic hormones, estrogen, EGF, and VEGF, pre-
activates the UPR, anticipating future requirements for increased protein folding capacity.12–14 
Demonstrating clinical relevance, data from ~1000 estrogen receptor α positive (ERα+) breast 
cancers shows that activating a UPR gene signature is a powerful prognostic marker, tightly 




     Strong and sustained activation of the reactive UPR induces caspase-dependent apoptosis. 
Activation of PERK inhibits translation of most mRNAs, increasing translation of ATF4 
(activating transcription factor 4). ATF4 induces the transcription factor CHOP (C/EBP 
homologous protein) and subsequently GADD34 (growth arrest and DNA-damage-inducible 
protein 34).1,2,50–52 When these factors reach a critical threshold and the UPR-activating stress 
cannot be resolved, apoptosis is triggered.1,2,50–52 
     The consequences of strong and sustained activation of the anticipatory UPR were largely 
unknown. We described a small molecule, BHPI, that is a potent preclinical anticancer 
drug.15,29,36,80 Unlike inhibitors targeting the reactive UPR, BHPI works by inducing 
hyperactivation of the anticipatory UPR.29,35,52,105,106 BHPI acts through ERα to induce rapid 
activation of phospholipase C γ (PLCγ), which cleaves PIP2 to diacylglycerol (DAG) and inositol 
triphosphate (IP3). IP3 then binds to and opens IP3 receptors (IP3Rs) in the EnR membrane, 
allowing efflux of calcium stored in the lumen of the EnR into the cell body. This robust and 
sustained calcium efflux leads to strong and sustained activation of all three arms of the UPR.29 
Through this pathway, BHPI blocks proliferation of, and often kills, ERα+ breast, endometrial, and 
ovarian cancer cells.15,29,36 
     Here we describe how sustained activation of the anticipatory UPR by BHPI kills cancer cells. 
In contrast to classical UPR activators that kill cells through caspase-dependent apoptosis,50–52 
BHPI hyperactivates the anticipatory UPR; this causes ATP depletion leading to cell death by a 
necrosis-like mechanism. Notably, in parallel with necrosis, hyperactivation of the anticipatory 






BHPI Kills ERα+ Breast and Endometrial Cancer Cells 
     BHPI targets ERα+ cancer cells by inducing activation of the anticipatory UPR.29,36 In cell 
culture, conventional endocrine therapies for breast cancer, tamoxifen and fulvestrant/ICI 182,780 
(ICI), inhibit estrogen-ERα-dependent proliferation and usually do not kill cancer cells. To explore 
whether BHPI induces cell death, we performed proliferation assays using tamoxifen-resistant 
TamR cells,107 T47D cells, and cell lines expressing ERα mutations common in metastatic breast 
cancer: T47D-ERαY537S (TYS) and T47D-ERαD538G (TDG).15 BHPI not only blocked growth, 
but also reduced cell number below that initially plated, indicating cell death (Figure 13a,b). To 
better quantify cell death, we used an automated assay for cell viability, trypan blue exclusion. 
Consistent with action through ERα, BHPI caused cell death in as little as 24 hours in ERα+ cell 
lines, but not in ERα- cell lines (Figure 13c-e). 
 
 
Figure 13. BHPI kills ERα+ breast and endometrial cancer cells. (a) TamR cell proliferation after 
4 days in 8% charcoal:dextran-treated calf (CD-calf) serum with the indicated treatments:      
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Figure 13 (cont.) E2 100 pM; z-4-hydroxytamoxifen (OHT, the active form of tamoxifen) 1 µM; 
ICI/fulvestrant 1 µM; BHPI 100 nM. (•) Indicates starting cell number (day 0). (b) Dose-response 
study of the effect of increasing concentrations of BHPI on proliferation of T47D, TYS, and TDG 
cells after 4 days. (a, b) Alamar-blue assays; (n=8 biological replicate experiments). (c) Automated 
trypan blue exclusion assays of ERα-positive cells after 24 hr treatment with 1 µM BHPI. (d) 
Trypan blue exclusion assays of ERα-negative cells after 24 hr treatment with 1 µM BHPI. (e) 
Trypan blue exclusion assays of isogenic MCF10A and MCF10AER IN9 cells after 24-hour 
treatment with 1 µM BHPI. (c-e) Data is mean ± s.e.m (n=3 biological replicate experiments). For 
(c-e) **p<0.01, ***p<0.001, n.s. = not significant by Student’s T-test. 
 
Unlike Classical UPR Activators, BHPI Does Not Induce Caspase-dependent Apoptosis 
     Consistent with activation of caspase-dependent apoptosis, the pan-caspase inhibitor Q-VD-
OPH blocks cell death induced by reactive UPR activators, thapsigargin (THG) and bortezomib 
(BORT) (Figure 14a).50–52,108 In contrast, BHPI-induced cell death through hyperactivation of the 
anticipatory UPR is not blocked by the pan-caspase inhibitors Q-VD-OPH or Z-VAD-FMK at 1 
(TYS) or 24 hours (T47D and TDG) (Figures 14b and 15a), or by transient overexpression of Bcl2 
in TYS cells (Figure 14c). Furthermore, Z-VAD-FMK had no effect on BHPI’s ability to block 
growth of T47D, TYS, or TDG cells over 4 days (Figure 15b). Consistent with earlier reports of 
impaired caspase-dependent apoptosis in MCF-7 and T47D cells,109–111 we saw only minor PARP 
(poly ADP-ribose polymerase) cleavage upon treatment of T47D, BT-474, or ECC-1 cells with 
the apoptosis-inducer and general protein kinase inhibitor staurosporine (STS), as well as no 
visible PARP cleavage with BHPI up to 48 hours (Figure 14d). Characteristic of apoptotic cell 
death, STS-treatment of TYS cells caused a distinct increase in Annexin V-FITC staining, 
followed by propidium iodide (PI) uptake into cells, as determined by flow cytometry. In contrast, 
BHPI-treated cells exhibited a markedly different staining pattern (Figure 15c,d). 
    Reactive UPR activators upregulate the mediator of the UPR-induced apoptotic cascade, 
CHOP.112–114 We show BHPI upregulates CHOP mRNA, but due to rapid, sustained, near-
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quantitative inhibition of protein synthesis through PERK activation,29 CHOP protein is never 
made (Figure 14e). 
 
 
Figure 14. BHPI does not induce caspase-dependent apoptosis. (a) Trypan blue exclusion assay 
of T47D cells after 24 hr treatment with or without 20 µM Q-VD-OPH, 100 nM bortezomib 
(BORT), or 10 µM thapsigargin (THG). (b) Trypan blue exclusion assay of T47D and TDG cells 
after 24 hr, and TYS cells after 1 hr treatment with: 1 µM BHPI with or without 20 µM Q-VD-
OPH. (c) Trypan blue exclusion assay and western blot analysis of TYS cells infected with 
lentivirus expressing luciferase (LV-luc) or Bcl2 (LV-Bcl2) after 1 hr treatment with 1 µM BHPI. 
(a,b,c) Data is mean ± s.e.m (n=3 biological replicate experiments), *p<0.05, **p<0.01, 
***p<0.001, n.s.= not significant by Student’s T-test. (d) Western blot analysis of cleaved PARP 
(arrow) in T47D and BT-474 breast cancer cells, and ECC-1 endometrial cancer cells after 
treatment with 1 µM BHPI or 5 µM staurosporine (STS) for the indicated times. (e) mRNA and 
western blot analysis of CHOP induction in T47D cells treated with 1 µM BHPI or 300 nM 





Figure 15. BHPI does not kill cells through apoptosis. (a) Trypan blue exclusion assay of T47D 
and TDG cells after 24 hr, and TYS cells after 1 hr treatment with: 1 µM BHPI with or without 20 
µM Z-VAD-FMK. (b) T47D, TYS, and TDG cell proliferation after 4 days in complete           
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Figure 15 (cont.) growth medium with the indicated concentration of BHPI with or without 20 
µM Z-VAD-FMK. Alamar-blue assay. (•) indicates initial number of cells plated. (c) 
Representative flow cytometry histograms of annexin V-FITC (FITC) and propidium iodide (PI) 
staining of TYS cells after treatment with 5 µM staurosporine (STS) for 8 hours or 1 µM BHPI for 
the indicated times. (d) Percent annexin V-FITC (FITC) and/or propidium iodide (PI) positive 
TYS cells relative to vehicle control. Data is mean ± s.e.m (a,c) (n=3 biological replicate 
experiments); (b) (n=8 biological replicate experiments) *p<0.05, **p<0.01, ***p<0.001, n.s. = 
not significant by Student’s T-test. 
 
BHPI Does Not Upregulate Autophagy 
     The contribution of autophagy to cancer is complex. Mild induction of autophagy is protective, 
while extended activation is toxic.115–117 Using the inhibitor of lysosomal acidification, 
chloroquine (CQ), we blocked turnover of proteins in the autophagosome and monitored the 
production of the autophagy marker LC3-II.115,116 Surprisingly, BHPI down-regulated LC3-II in 
T47D, TYS, TDG, and ECC-1 cells (Figure 16a). A second autophagy marker, Beclin-1,115,118 was 
unchanged or down-regulated in T47D, TYS, and TDG cells (Figure 16b). Lastly, we probed the 
central regulator of cell metabolism, mTOR (mammalian target of rapamycin). Nutritional 
deficiency inhibits mTOR and activates autophagy.115,119,120 To monitor mTOR activation, we 
looked at a downstream readout of active mTOR, phosphorylated p70S6K. Similar to 24-hour 
serum starvation, BHPI caused a transient decrease in p70S6K phosphorylation at 8 hours, but 
p70S6K phosphorylation recovered and was stable from 16-48 hours (Figure 16c). This indicates 




Figure 16. Autophagy is not upregulated by BHPI. (a) Western blot analysis of LC3-II production 
(arrow) in T47D, TYS, TDG, and ECC-1 cells after treatment with 1 µM BHPI, 30 µM 
Chloroquine (CQ), or BHPI + CQ for the indicated times. (b) Western blot analysis of Beclin-1 
levels in T47D, TYS, and TDG cells after treatment with 1 µM BHPI for the indicated times. (c) 
Western blot analysis of phosphorylation of p70S6K in T47D cells after treatment with 1 µM BHPI 
for the indicated times, or after serum starvation (Starve) for 24 hrs. 
 
BHPI Induces Rapid Swelling of Cancer Cells 
     While there was no evidence for BHPI-induced programmed cell death, we noticed that hours 
after BHPI treatment, cells appeared swollen. Swelling is associated with diverse lethal 
pathologies, including edema, hypertrophy, and necrosis.121 BHPI, but not the inactive 
structurally-related compound 8, caused concentration-dependent cell swelling (Figure 17a).29 
Cell swelling is ERα-dependent; ERα+ cell lines exhibited significant swelling within 1 hour, while 
ERα- cell lines did not (Figure 18a,b). Moreover, siRNA knockdown of ERα (ESR1) significantly 
attenuated swelling. Since knockdown was incomplete and BHPI is an extremely potent activator 
of the anticipatory UPR, some residual swelling was observed (Figure 17b). Interestingly, rapid 
swelling was closely followed by an increase in death in TYS and MCF-7 cells (Figure 18c). 
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    The mitogenic hormones estrogen (E2), EGF, and progesterone (P4) weakly activate the 
anticipatory UPR.13–15 Demonstrating the unique ability of BHPI to cause cell swelling, weak 
activation of the anticipatory UPR by E2, EGF, and P4 did not induce swelling (Figure 17c). 
Additionally, reactive UPR activators bortezomib (BORT) and tunicamycin (TUN) did not cause 
swelling (Figure 17d). Although the reactive UPR activator THG and BHPI produce similar 
increases in cytosolic calcium,29 THG did not cause swelling (Figure 17e). Moreover, the 
endocrine therapies z-4-hydroxytamoxifen (OHT) and ICI/fulvestrant or the chemotherapeutic 
doxorubicin (DOX) did not cause cell swelling, and paclitaxel (PAC) caused minimal swelling 
(Figure 17d).  
     Since BHPI was unique in its ability to cause rapid swelling, we asked whether this was specific 
to hyperactivation of the anticipatory UPR. We showed that 2-APB completely blocks calcium 
release from EnR IP3R channels following BHPI treatment and after weak activation of the 
anticipatory UPR.14,29,122 2-APB blocked BHPI-induced swelling (Figure 18d). Supporting BHPI 
acting through anticipatory UPR hyperactivation, BHPI induced swelling in T47D cells 
maintained in calcium-free medium (Figure 18d). Moreover, the calcium chelator, BAPTA-AM, 
completely blocked swelling (Figure 18d). We hypothesized that BHPI might be eliciting cell 
swelling by modulating ion channels. However, inhibitors targeting individual ion channels/pumps 
did not block swelling (Figure 18e). Since BHPI was not able to swell cells in salt-free, isosmotic 
medium, extracellular ions are necessary for BHPI-induced swelling (Figure 18f). Taken together, 
this suggests that BHPI hyperactivation of the anticipatory UPR triggers cell swelling, and that 






Figure 17. BHPI-ERα-induced cell swelling is linked to early steps in the anticipatory UPR. (a) 
Cell volume in ERα-positive cells treated with 1 µM BHPI for 1 hr (T47D, TYS, TDG, MCF-7 
and BT-474), or 30 min (ECC-1). (b) Cell volume in ERα-negative MDA MB-231, MCF10A, 
HeLa, and ES2 cells treated with 1 µM BHPI for 1 hr. (c) Time course of the effect of BHPI on 
cell volume and cell death in TYS and MCF-7 cells. Cell volume (solid lines) and cell death 
(dashed lines) were assayed by trypan blue exclusion in cells treated with 50 nM BHPI (TYS), or 
100 nM BHPI (MCF-7). (d) Blocking the increase in intracellular calcium with 2-APB, or with 
the calcium chelator, BAPTA-AM (BAPTA), prevents the BHPI-induced increase in cell volume. 
Cell volume in T47D cells treated for 1 hr with vehicle, 50 nM BHPI, 100 µM 2-APB, or BHPI + 
2-APB in calcium-free isosmotic medium, or vehicle, 20 µM BAPTA-AM, or BHPI + BAPTA-
AM. (e,f) Cell volume of T47D cells after 1 hr treatment as indicated. (e) BHPI 50 nM; ouabain 2 
µM (Na+/K+ ATPase inhibitor); niflumic acid (NFA) 100 µM (nonspecific anion channel 
inhibitor); SKF96365 10 µM (TRP channel inhibitor). (f) BHPI 50 nM; isosmotic salt-free sucrose 
buffer (No Salt). Data is mean ± s.e.m (n=3 biological replicate experiments) *p<0.05, **p<0.01, 





Figure 18. BHPI-induced cell swelling is ERα-dependent and unique to anticipatory 
hyperactivation of the UPR. (a) Dose-response study of cell volume in T47D cells treated for 1 hr 
with the indicated concentrations of BHPI, or the inactive structurally-related compound 8 (Cmpd 
8). (b) Effect of reducing ERα levels on cell volume and western blot analysis of ERα in T47D 
cells. Cells were plated and treated with non-coding (siNC) or ERα (siERα) siRNA for 16 hr. 24 
hr later, cells were treated with ICI for 24 hr to further reduce the levels of ERα before 
measurement of cell volume in T47D cells treated with vehicle or 1 µM BHPI for 1 hr, with the 
indicated pre-treatment: non-coding siRNA 100 nM; ERα siRNA 100 nM + ICI 1 µM. (c-e) Cell 
volume of T47D cells after the indicated treatments for 1 hr, or as noted. z-4-hydroxytamoxifen 
(OHT) 1 µM; ICI 1 µM; paclitaxel (PAC) 1 µM; doxorubicin (DOX) 1 µM; bortezomib (BORT) 
100 nM; tunicamycin (TUN) 10 µg/mL; thapsigargin (THG) 1 µM. Data is mean ± s.e.m (n=3 
biological replicate experiments) *p<0.05, **p<0.01, ***p<0.001, n.s. = not significant by 
Student’s T-test. 
 
BHPI Activation of cPLA2 Leads to Arachidonic Acid Release 
     Calcium signaling and membrane stretching activate cytosolic phospholipases A2 (cPLA2s), 
resulting in cleavage of membrane phospholipids to form arachidonic acid (AA).123–125 AA and its 
metabolites can further alter cell volume by modulating the activity of ion channels.126 
Additionally, AA induces death in glial cells.127 BHPI elicited time-dependent AA release in T47D 
cells and AA release correlated with cell swelling (Figure 19a). Furthermore, within 1 hour, BHPI 
induced concentration-dependent release of AA from several cell lines (Figure 19b). Neither 
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control compound 8 (Figure 20a) nor THG (Figure 19c) caused release of AA, but THG was able 
to block BHPI-induced AA release (Figure 19c). Importantly, THG did not block swelling in T47D 
or TYS cells, indicating membrane stretching is not sufficient to activate cPLA2 (Figure 20b). 
Consistent with cPLA2 as the source of AA, the cPLA2 inhibitor quinacrine (Quin) blocked release 
of AA from T47D cells (Figure 19c). Suggesting AA contributes minimally to cell swelling, 
adding AA to culture medium increased cell size modestly (Figure 20c). Additionally, while Quin 
blocked cell swelling, the block was only partially reversed by adding back AA (Figure 19d).  
     Demonstrating that neither AA release nor cell swelling are directly related to rapid cell death, 
while Quin blocked both AA release and swelling, it did not block death in TYS cells, which die 
rapidly following BHPI treatment (Figure 19e). Although AA is the precursor for pro-
inflammatory prostaglandins, BHPI treatment for 24 hours only elicited a minimal increase in 






Figure 19. BHPI activation of cPLA2 causes release of arachidonic acid (AA). (a) Time course 
showing a correlation between increased AA release and increased cell volume in BHPI-treated 
T47D cells. Time course of changes in cell volume (solid bars) and 3H-arachidonic acid release 
([3H]AA, hatched bars) after treatment of T47D cells with vehicle or with 10 µM BHPI. Data is 
mean ± s.e.m (solid bars, n=3 biological replicate experiments; hatched bars, n=4 biological 
replicate experiments). (b) Concentration-dependent release of [3H]AA from T47D, TYS, TDG, 
and MCF-7 cell membranes after treatment for 45 min with vehicle or the indicated concentration 
of BHPI. Positive control (Pos Ctl) is 150 mOsm buffer with 1 µM THG. (c) THG and the cPLA2 
inhibitor quinacrine (Quin) block the BHPI-mediated increase in AA. Release of [3H]AA from 
T47D cell membranes after treatment for 45 min with vehicle, 1 µM thapsigargin (THG), 1 µM 
BHPI, BHPI + THG, 300 µM Quin, or BHPI + Quin. (d) Effect of Quin and AA on BHPI-induced 
changes in cell volume. Volume of T47D, TYS, TDG, and MCF-7 cells after treatment for 1 hr 
with vehicle, 50 nM BHPI, 300 µM Quin, 250 µM AA, BHPI + Quin, or BHPI + Quin + AA. (e) 
Quin does not block BHPI-induced cell death. Trypan blue exclusion assay for cell death in TYS 
cells treated for 1 hr with vehicle, 1 µM BHPI, 300 µM Quin, or BHPI + Quin. (f) ELISA 
determination of prostaglandin production from T47D cells after treatment for 24 hr with 10 µM 
BHPI. Data is mean ± s.e.m (b,c,f) (n=4 biological replicate experiments), (d-e) (n=3 biological 






Figure 20. AA only modestly modulates cell volume. (a) Release of [3H]AA after 45 min treatment 
with inactive BHPI relative, compound 8. (b) THG does not block the BHPI-mediated increase in 
cell volume. Cell volume in T47D and TYS cells treated for 1 hr with vehicle, 1 µM THG, 25 or 
50 nM BHPI and 25 or 50 nM BHPI + THG. (c) Dose-response study of the effect of AA on cell 
volume. T47D cells were treated for 1 hr with the indicated concentrations of AA. Data is mean ± 
s.e.m. For (a) (n=4 biological replicate experiments), (b,c) (n=3 biological replicate experiments) 
*p<0.05, **p<0.01, ***p<0.001, n.s. = not significant by Student’s T-test. 
 
BHPI Induces Necrotic Cell Death 
     While neither swelling nor AA production is responsible for rapid cell death, they are associated 
with inflammatory forms of cell death, such as necrosis. Necrotic cell death has fewer well-defined 
markers than apoptosis or autophagy; necrosis often involves disruption of calcium homeostasis, 
cell swelling, ATP depletion and, ultimately, loss of plasma membrane integrity.38,56,130,131 We 
observed loss of membrane integrity in T47D, TYS, and TDG cells by monitoring leakage of 
cellular HMGB1 (high mobility group box 1) (Figure 21a) and LDH (lactate dehydrogenase) into 
the medium (Figure 22a). Necrosis is best assessed by morphological changes visualized by 
transmission electron microscopy (TEM). TEM images of T47D, TYS, and TDG cells treated with 
BHPI for 24 or 48 hours revealed morphological changes characteristic of necrosis, including 
lysosomal and mitochondrial swelling, translucent cytoplasm, and ultimately, plasma membrane 
disintegration (Figures 21b and 22b).56,131,132 Cells treated with BHPI were similar to cells treated 
with a necrosis-inducing concentration of H2O2 for 24 hours (Figure 22b).133 
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     There is increasing interest in programmed necrosis, or necroptosis. Initiation of necroptosis by 
diverse stimuli requires receptor-interacting proteins 1 or 3 (RIP1, RIP3).134,135 To test the 
involvement of RIP1 and RIP3, we used the inhibitors 7-Cl-O-Nec-1 (Nec-1) and GSK872, 
respectively. Nec-1 and GSK872 did not reduce killing by BHPI at 1 (TYS) or 24 hours (T47D 
and TDG), failed to restore proliferation over 4 days, and instead, increased cell death (Figure 
22c,d). Independent of necroptosis, these compounds are known to inhibit cell proliferation and 
induce apoptosis.135,136 
Figure 21. BHPI-induced cell death exhibits a necrotic phenotype. (a) Western blot analysis of 
HMGB1 release into the cell culture supernatant at the indicated time points from T47D, TYS, and 
TDG cells treated with 1 µM BHPI. Equal volumes of culture supernatant were loaded for analysis. 
(b) Transmission electron microscopy (TEM) images of T47D, TYS, and TDG cells treated with 
1 µM BHPI for 0 or 24 hr. Letters with arrows indicate features characteristic of necrotic 
morphology: (A) swollen vacuoles, (B) swollen mitochondria, (C) cytoplasmic lightening (D) 
membrane rupture/“ghost” cells. 
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Figure 22. BHPI induces necrotic, but not necroptotic, cell death. (a) Lactate dehydrogenase 
(LDH) release into the cell culture supernatant at the indicated times after treatment of T47D, TYS, 
and TDG cells with 1 µM BHPI. Data is mean ± s.e.m (n=4 biological replicate experiments). (b) 
Transmission electron microscopy images of T47D and TDG cells treated with 1 µM BHPI for 48 
hr, or T47D cells treated with 3 mM H2O2 for 24 hr. Arrows indicate cells that have lost membrane 
integrity and have leaked cytosolic contents to become “ghost” cells. (c) Trypan blue exclusion 
assays of T47D and TDG cells treated for 24 hr or TYS cells treated for 1 hr as indicated: BHPI 1 
µM; Nec-1 100 µM; GSK872 5 µM. Data is mean ± s.e.m (n=3 biological replicate experiments), 
*p<0.05, **p<0.01, ***p<0.001, n.s. = not significant by Student’s T-test. (d) T47D cell 
proliferation after 4 days treatment in 10% CD-calf serum with the indicated treatment: E2 100 
pM; 7-Cl-O-Nec-1 (Nec-1) 100 µM; GSK872 (GSK) 5 µM. Alamar-blue assay. Data is mean ± 
s.e.m (n=8 biological replicate experiments). 
 
 
Necrotic Death Is an Early Outcome of Anticipatory UPR Hyperactivation and ATP 
Depletion Is Critical 
     BHPI-induced hyperactivation of the anticipatory UPR results in robust PERK activation and 
rapid, near-quantitative inhibition of protein synthesis at initiation.29 The potent activator of eIF2B, 
ISRIB, reversed BHPI-induced inhibition of protein synthesis (Figure 23a).137 At later times, BHPI 
also inhibits protein synthesis at elongation, through activation of AMPK and phosphorylation of 
eEF2; and ISRIB did not reverse inhibition of protein synthesis (Figure 24a).29 While ISRIB 
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completely blocked BHPI-induced inhibition of protein synthesis, it did not block rapid necrotic 
death in TYS cells (Figure 23b). 
     We next asked if events upstream of PERK activation in the anticipatory UPR trigger necrosis, 
specifically, calcium release from IP3Rs. Over several days, knockdown of some essential 
components of the anticipatory UPR, such as all three IP3R calcium channel isoforms, results in 
substantial damage to cells. Moreover, the powerful IP3R signal induced by hyperactivation of the 
anticipatory UPR could not be blocked by the IP3 sponge, or by IP3 phosphatase.13,138 Notably, 2-
APB completely blocked rapid cell death in TYS and MCF-7 cells (Figure 23c). Demonstrating 
PLCγ activation and IP3 production are necessary for rapid cell death, siRNA knockdown of PLCγ 
nearly abolished BHPI-induced cell death (Figure 24b). 
     IP3 binds to and opens IP3 receptor (IP3R) calcium channels causing a rapid and sustained 
release of calcium from the lumen of the EnR into the cytosol.29,122 This creates an ATP-depleting 
futile cycle, where energy-dependent EnR SERCA pumps try to restore calcium homeostasis by 
pumping the calcium back into the lumen of the EnR, only to have it leak back out due to sustained 
opening of IP3Rs.29,122 Strikingly, the inhibitor of the SERCA pump, THG, significantly reduced 
rapid BHPI-induced cell death in TYS and MCF-7 cells (Figure 23d). We previously showed that 
in MCF-7 cells, THG blocks BHPI-induced ATP depletion.29 Consistent with a critical role for 
ATP depletion in BHPI-induced necrotic death, BHPI caused significant ATP depletion in TYS 
cells within 1 hour that was blocked by THG (Figure 23e). We therefore compared the time course 
of BHPI-induced ATP depletion with the time course of cell death (note that the apparent increase 
in cell viability at 24 hours in TYS cells in Figure 23e is due to ~23% loss of disintegrated dead 
cells that are not visualized as trypan blue positive, we estimate viability to be 59%). Supporting 
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a central role for ATP depletion in cell death, the time course of the onset of necrotic cell death in 
T47D, TYS, and TDG cells is correlated with the onset of ATP depletion (Figure 23e). 
  
 
Figure 23. BHPI-induced necrosis is an upstream effect of anticipatory UPR activation and 
requires ATP depletion. (a) Incorporation of 35S-methionine into newly synthesized protein in TYS 
cells treated for 1 hr with vehicle (set to 100%), 50 nM BHPI, 200 nM ISRIB, BHPI + ISRIB, or 
10 µM cyclohexamide (CHX). (b) ISRIB does not prevent BHPI-induced cell death. Trypan blue 
exclusion assay for cell death in TYS cells after 1 hr treatment with vehicle, 1 µM BHPI, 200 nM 
ISRIB, or BHPI + ISRIB. (c) Locking the EnR IP3R calcium channels closed with 2-APB blocks 
BHPI-induced cell death. Trypan blue exclusion assay for cell death in MCF-7 and TYS cells 
treated for 1 hr with vehicle, 1 µM BHPI, 100 µM 2-APB, or BHPI + 2-APB. (d) THG inhibits 
BHPI-induced cell death. Trypan blue exclusion assay for cell death in TYS and MCF-7 cells 
treated for 1 hr with vehicle, 1 µM BHPI, 10 µM THG, or BHPI + THG. (e) Time-dependent 
decline in ATP levels in BHPI-treated cells correlates with cell death. Measurement of whole-cell 
ATP levels (bars) and trypan blue exclusion (overlay, [o]) after treatment for the indicated times 
with vehicle, 1 µM BHPI, 10 µM THG, or BHPI + THG. For TYS cells, ~23% of cells have died 
at early times and disintegrated at 24 hr and are not counted by the instrument. Therefore, the 
percentage of trypan blue excluding cells declines at 24 hr, the total number of dead cells (trypan 
blue positive + disintegrated cells) is estimated to be ~59%. Data is mean ± s.e.m (a) (n=4 
biological replicate experiments), (b-d) (n=3 biological replicate experiments), (e) (n=5 biological 
replicate experiments; ATP) (n=3 biological replicate experiments; cell viability) *p<0.05, 





Figure 24. BHPI-induced necrosis requires activation of the anticipatory UPR through PLCγ. (a) 
Incorporation of 35S-methionine into newly synthesized protein in TYS cells treated for 4 hr with 
vehicle, 50 nM BHPI, 0.2 or 1 µM ISRIB, or 0.2 or 1 µM ISRIB + 50 nM BHPI. Data is mean ± 
s.e.m (n=4 biological replicate experiments). (b) Trypan blue exclusion assay and western blot 
analysis of TYS cells. Cells were treated with 100 nM non-coding (siNC) or PLCγ (siPLCγ) siRNA 
for 16 hr. 48 hr following transfection, cells were treated with 50 nM BHPI for 2 hr before analysis. 
Data is mean ± s.e.m (n=3 biological replicate experiments) *p<0.05, **p<0.01, ***p<0.001, n.s. 
= not significant by Student’s T-test. 
 
Necrotic Products Released From BHPI-treated Cells Upregulate Inflammatory Markers 
and Increase Migration in THP-1 Cells 
     THP-1 cells are a commonly used human monocytic cell line that can be differentiated into 
macrophage. Using conditioned medium from T47D or TYS cells treated with vehicle or BHPI 
for 24 hours, we were able to show that necrotic products released from ERa+ cancer cells caused 
induction of inflammatory mRNAs in THP-1 macrophage (Figure 25a) and increased migration in 
THP-1 monocytes (Figure 25b). Interestingly, conditioned medium from necrotic cells caused 





Figure 25. Conditioned medium from necrotic T47D and TYS cells causes an inflammatory 
response in THP-1 cells. (a) mRNA analysis of induction of inflammatory markers in THP-1 
macrophage. Differentiated THP-1 cells were incubated for 6 hr with conditioned medium from 
TYS cells that had been treated with vehicle or 1 µM BHPI for 24 hr. (b) Fluorometric analysis of 
migration of THP-1 monocytes through a 5 µm filter. THP-1 cells were allowed to migrate for 4 
hr towards conditioned medium from T47D or TYS cells that had been treated with vehicle, 10 
µM Raptinal, or 1 µM BHPI for 24 hr. (c) Trypan blue exclusion assay of T47D and TYS cells 
treated with vehicle, 10 µM Raptinal, or 1 µM BHPI for 24 hr. Data is mean ± s.e.m (n=3 biological 
replicate experiments) *p<0.05, **p<0.01, ***p<0.001, n.s. = not significant by Student’s T-test. 
 
Discussion 
     Tumors must proliferate and overcome hypoxia, nutritional deprivation, and stress due to 
chemotherapy. In response, tumors activate the reactive UPR, which helps them overcome the 
stress, survive, and metastasize.27 Activation of key UPR components, including 
BiP/GRP78/HSPA5 and XBP1, is implicated in development of diverse cancers including breast, 
lymphoma, lung, and glioma.28 Although strong and sustained activation of the reactive UPR 
triggers caspase-dependent apoptosis, most drugs that target the reactive UPR usually work by 
inhibiting action of a UPR component and therefore must avoid toxicity in cells with a high 
secretory load.35,52,105,106 An attractive alternative is targeting the anticipatory UPR that we, and 
others, showed is activated by the mitogenic hormones estrogen, progesterone, EGF, and VEGF.12–
14 Instead of inhibiting a component of this pathway, BHPI exploits the moderate activation of this 
protective pathway in ERα+ cancer cells by hyperactivating the anticipatory UPR.29 This pushes 
UPR activation in ERα+ cancer cells into the lethal range. Thus, BHPI is both a promising 
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preclinical anticancer drug with a unique mode of action,29,36 and a powerful tool for analyzing the 
death pathway induced by strong and sustained activation of the anticipatory UPR. 
     A unique feature of strong and sustained activation of the anticipatory UPR is rapid ATP 
depletion. Well-studied activators of the reactive UPR do not induce ATP depletion. Therefore, 
the consequences for cancer cell fate of BHPI-induced hyperactivation of the anticipatory UPR, 
sustained opening of IP3R calcium channels, and subsequent ATP depletion were unclear. 
     We explored the relationships between three events triggered by BHPI treatment: rapid cell 
swelling, release of arachidonic acid, and cell death. A model depicting our findings is Figure 26. 
The most striking consequence of anticipatory UPR activation, disruption of calcium homeostasis, 
and ATP depletion is necrotic cell death.56 Consistent with necrosis, we observed increased 
membrane permeability shown by leakage of intracellular proteins such as HMGB1 and LDH 
(Figures 21a and 22a). Furthermore, TEM images of T47D, TYS, and TDG cells treated with BHPI 
showed classical features of necrotic morphology including lysosomal and mitochondrial swelling 
and lightening of the cytoplasm (Figure 21b). At high concentrations, H2O2 induces disruption of 
calcium homeostasis, ATP depletion, and necrosis.56,131,133,139 Consistent with BHPI inducing 
necrotic cell death, BHPI and H2O2-treated cells exhibited similar morphology. Notably, after 24 
hours in TYS cells or 48 hours in T47D and TDG cells, we observed a “ghost” cell population 
exhibiting severely disintegrated membranes and massive leakage of intracellular contents 


























Figure 26. Model depicting events that follow BHPI hyperactivation of the anticipatory UPR. 
UPR hyperactivation triggers three parallel events: cell swelling, arachidonic acid release, and 
necrotic cell death. Activation of PLCγ leads to production of IP3. Opening of IP3R calcium 
channels in the endoplasmic reticulum results in efflux of calcium from the lumen of the 
endoplasmic reticulum into the cell body. This calcium release is necessary for cell swelling. 
Pumping of cytosol calcium back into the lumen of the endoplasmic reticulum, by ATP-dependent 
SERCA pumps, and calcium leaking back out through the open IP3Rs causes an ATP-depleting 
futile cycle necessary for both arachidonic acid release and necrotic cell death. 
 
     Cytosolic calcium overload, such as is seen with BHPI-opening of EnR IP3R calcium channels, 
is implicated in both apoptosis and necrosis.39 Demonstrating calcium release from IP3Rs is 
necessary for cell death, 2-APB completely blocked rapid death in TYS and MCF-7 cells (Figure 
23c). Prolonged activation of the reactive UPR results in apoptotic cell death. However, near-
quantitative inhibition of protein synthesis by BHPI blocks production of pro-apoptotic UPR 
mediators, such as CHOP (Figure 14e). Interestingly, we also observed inhibition of autophagy 
upon BHPI treatment (Figure 16). It is possible that the reduced requirement for amino acids due 
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to near quantitative inhibition of protein synthesis by BHPI is linked to inhibition of autophagy. 
Inhibiting autophagy, may exacerbate BHPI-induced UPR activation and ATP depletion, and 
consequently, necrotic cell death.  
     Programmed cell death by apoptosis and autophagy require ATP; activation of caspase-9 in the 
apoptosome and phagophore elongation are ATP-dependent.55 When ATP is depleted, cells fail to 
initiate apoptosis and/or autophagy, and necrotic cell death is induced.39 Commonly, necrotic ATP 
depletion is caused by mitochondrial dysfunction after disruption of calcium homeostasis.140 In 
contrast, BHPI indirectly activates SERCA pumps, causing cells to consume ATP faster than they 
produce it, a mechanism reminiscent of PARP-mediated ATP depletion after excessive DNA 
damage.131 We analyzed the role of ATP depletion using THG, which inhibits ATP-dependent 
SERCA pumps in the EnR and reverses BHPI-mediated ATP depletion.29 Consistent with loss of 
ATP playing a pivotal role in activating necrotic cell death, and despite inducing an increase in 
intracellular calcium similar to that seen with BHPI,29 THG potently reversed rapid death in TYS 
and MCF-7 cells (Figure 23d). Since THG is lethal over time,51 we could not test the effect of 
THG on T47D and TDG cells. Supporting a role for ATP depletion in necrotic cell death following 
sustained activation of the anticipatory UPR, death and ATP depletion were correlated in T47D, 
TYS, and TDG cells (Figure 23e). Notably, in TYS cells, but not in T47D and TDG cells, BHPI 
induces both a decline in ATP levels and cell viability in 1 hour. 
     Within 1 hour and prior to cell death, BHPI caused ERα-mediated, time and concentration-
dependent cell swelling (Figures 17a,b and 18a-c). Cell swelling is associated with and is 
commonly a precursor to necrosis.121 Swelling was specific to BHPI’s unique mechanism of action 
and required ERα, opening of EnR IP3R calcium channels, intracellular calcium, and extracellular 
ions (Figure 18d,f). Weak anticipatory UPR activators, reactive UPR activators, endocrine 
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therapies, and chemotherapeutic drugs did not cause cell swelling (Figure 17c-e). Notably, 
blocking BHPI-mediated ATP depletion with THG did not inhibit rapid swelling (Figure 20c), but 
did block death (Figure 23d). 
     In contrast, ATP depletion was required for cPLA2 activation as THG blocked AA release from 
membranes (Figure 19c). While assaying ATP levels in the entire T47D cell at 1 hour did not show 
ATP depletion, it is possible that local ATP levels at membranes are reduced. Interestingly, while 
calcium activates cPLA2,123–125 THG, which increases intracellular calcium but does not reduce 
ATP levels, did not induce AA release. Instead, THG blocked BHPI-mediated AA release (Figure 
19c). Additionally, even though both THG and the cPLA2 inhibitor Quin block AA release from 
cells, only Quin blocked cell swelling (Figure 19d). Within cells, AA can be converted to pro-
inflammatory prostaglandins by COX (cyclooxygenase).128,129 We saw a modest, not statistically 
significant, increase in prostaglandins in the medium from BHPI-treated cells. Together, BHPI-
mediated release of AA metabolites, and necrotic leakage of immunomodulatory proteins such as 
HMGB1, might create an inflammatory tumor environment conducive to increased immune 
detection and killing of tumor cells in vivo.142,143 Preliminary data from THP-1 cells indicates that 
the small molecules and proteins released from BHPI-treated necrotic cells are sufficient to 
activate macrophage and monocytes in vitro (Figure 25). 
     While we found that rapid cell swelling, AA release, and cell death are linked to early steps in 
sustained activation of the anticipatory UPR and require calcium release from IP3Rs, they are 
parallel and distinct results. Notably, ATP depletion independently activates cPLA2 and triggers 
necrotic cell death. This work demonstrates that in contrast to reactive UPR activators that kill 
cells through CHOP-mediated apoptosis, BHPI, a small-molecule activator of the anticipatory 
UPR, kills cells through necrosis. Importantly, ATP depletion is the critical cause of necrotic cell 
66 
 
death after strong and sustained activation of the anticipatory UPR. Thus, we show that different 




CHAPTER 5: DISCUSSION 
     It was previously unknown if BHPI could effectively target T47D breast cancer cells expressing 
the constitutively active mutations ERaY537S (TYS cells) and ERaD538G (TDG cells). In 3D 
culture, OHT and fulvestrant/ICI only partially inhibited growth of TYS and TDG cells and R5020 
completely reversed antiestrogen inhibition of growth. This resistance is consistent with recent 
studies and with data suggesting patients carrying metastatic tumors with these mutations have a 
poor prognosis.40,45 Additionally, TYS and TDG cells express higher levels of the molecular 
chaperones BiP and p58IPK and P4 further elevates some of these downstream products of mild 
UPR activation. Elevated expression of UPR components is known to be associated with cancer 
progression,30,31 and specifically, BiP is protective and contributes to antiestrogen resistance.144 In 
contrast to the antiestrogens, BHPI not only blocked the growth of, but killed TYS and TDG cells 
in the presence or absence of R5020. Since BHPI is not a competitive inhibitor of ERa and targets 
ERa positive cancer cells irrespective of their dependence on E2 for proliferation, it is a promising 
preclinical drug candidate for the treatment of metastatic breast cancers expressing these 
mutations. Moreover, BHPI qualitatively appears to target and kill TYS and TDG cells better than 
T47D cells expressing wildtype ERa. While yet untested, it is possible that the further mild and 
protective upregulation of the anticipatory UPR in TYS and TDG cells makes them more 
vulnerable to hyperactivation of the UPR by BHPI, and subsequent cell death. This idea is 
consistent with our finding that up-regulation of a UPR gene index in ERa positive breast cancer 
patients is tightly correlated with tamoxifen resistance, reduced time to recurrence, and a poor 
prognosis.14 
     Since BHPI effectively kills breast and endometrial cancer cell lines, including TYS and TDG 
cells, our next aim was to identify the cell death pathway it activates. Unlike most small molecules 
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that activate the classical reactive UPR, BHPI does not kill cells through CHOP and caspase-
dependent apoptosis. There is no evidence of caspase activation in the mechanism of cell death, 
and the cell morphology does not match shrinking and blebbing apoptotic cells. Additionally, 
BHPI does not activate, but rather seems to inhibit autophagy. Surprisingly, BHPI hyperactivation 
of the anticipatory UPR leads to necrotic cell death. We confirmed necrotic cell death morphology 
by observation of cell swelling, vacuolization and swelling of organelles, and eventual membrane 
rupture of T47D, TYS, and TDG cells, and by monitoring the release of cytosolic contents. 
Necrotic cell death is induced by disruption of calcium homeostasis through production of IP3 and 
opening of EnR IP3R channels, followed by an ATP-depleting futile cycle as energy-dependent 
SERCA pumps try to restore calcium homeostasis. Interestingly, rapid and dramatic ATP depletion 
is the critical step to initiate necrotic cell death. This was the first time that the death pathway 
induced by hyperactivation of the anticipatory UPR was described. 
     Given this mechanism of action of BHPI, we were curios to ask what the consequences of 
necrotic cell death induced by hyperactivation of the anticipatory UPR might be on the immune 
system. In an effort to increase immune responses to tumor antigens, recent goals of anti-cancer 
drug development include targeting immune checkpoints, identification of drugs that activate 
immunogenic cell death (ICD), and engineering oncolytic cancer vaccines.142,143,145 Of note, while 
necrotic cells produced through freeze-thaw cycles are not immunogenic, cells that have 
undergone necrosis after chemical modification with oxidizing agents or small molecules have 
shown exceptional potential.143 For example, necroptotic cancer cells effectively activate immune 
cells and vaccinate mice against a future tumor challenge.146 Despite intense interest in this area, 
necrotic cell death, caused by hyperactivation of the anticipatory UPR has never before been linked 
to activation of inflammatory signaling in immune cells. 
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     In addition to the release of AA from cancer cells, BHPI killing of cells through necrosis allows 
the release of a host of immunomodulatory small molecules and proteins including ATP, HMGB1, 
heat shock proteins, and IL-1a. These molecules are known to alter the activation, cytokine 
production, and migration potential of a variety of immune cells including monocytes, 
macrophage, and dendritic cells.147–150 Once activated, these cells can then go on to activate 
lymphoid cells, such as T cells, that target and help eliminate the cancer cells. While necrotic 
products released from T47D and TYS cells treated with BHPI activated THP-1 monocytes and 
macrophage, it is currently unclear what contribution the various necrotic products, including 
small molecules and proteins, make to this inflammatory response. In the future, it will also be 
important to understand how a coordinated and complex immune system recognizes and responds 
to a necrotic tumor in vivo. 
     After therapy, most ERa+ breast cancers go into remission. However, after many years, some 
cancers recur at the site of origin or as metastatic breast cancer due to residual or disseminated 
tumor cells. Metastatic cancers harboring mutations in ERa, including ERaY537S and 
ERaD538G, that recur are often resistant to classical endocrine therapy. It is thought that after 
treatment, and possibly up to 5 years preceding relapse, these cancerous cells lie dormant. 
Immunosurveilance has long been thought to play a role in encouraging dormancy of cancers.151,152 
It is therefore interesting to ask the following questions. First, will the necrotic cell death induced 
by BHPI activate an immune response in vivo? I have shown that BHPI effectively targets and 
kills endocrine therapy resistant cancer cells expressing ERaY537S and ERaD538G. Therefore, 
could BHPI treatment lead to a robust immune response that might completely wipe out every last 
cancer cell not effectively targeted by BHPI, especially those cancers that have developed 
resistance to classical therapies? And if not, could the potential immune response induced by BHPI 
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lead to production of cells, such as memory T cells, that could keep the residual cancer cells in a 
dormant state indefinitely? 
     BHPI is a unique small molecule with a novel mechanism of action, as it was the first molecule 
identified to induce necrotic cell death by hyperactivating the anticipatory UPR through ERa. Not 
only does it target diverse ERa+ breast, endometrial, and ovarian cancer cells, but it also effectively 
eliminates many ERa+ cancer cells that are resistant to current endocrine therapies, including those 
expressing mutations in the ERa LBD.15,29,153,154 Importantly, BHPI may recapitulate elements of 
immunotherapy in a small molecule, thereby synergizing with its potent ability to shrink tumors 
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